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ABSTRACT 
Microvesicles are heterogeneous population of micro-particles released 
constitutively and upon induction from healthy and unhealthy cells.  The role 
of cancer cell derived-MV in intercellular communication gains an intensive 
aria of research. The influence of leukaemia cell derived-MVs in this study 
was determined on normal prostate epithelial cell lines. PNT2 cells were 
treated with Jurkat cell derived-MVs lost epithelial characteristic (decreased 
epithelial marker E-cadherin) and gained mesenchymal phenotype 
(increased expression of mesenchymal marker Vimentin). 
TGF-β and intracellular Ca2+ concentration were partially involved in 
Epithelial Mesenchymal Transition (EMT) process. PNT2 cells acquire 
mesenchymal characteristic produced high level of resistances against 
apoptotic signals after exposed to serum starvation and anti-cancer drug 
docetaxel, produce excessive level of MMP-9 and 2/3 of total TPNT2 cell 
population were arrested   in the G2/M phase of the cell cycle, and halts cell 
proliferation. 
The influence of carcinoma cell derived-MVs on tumour microenvironment 
was examined through use of Non-small lung cancer cells (A549) derived-
MVs on primary lung fibroblasts (MRC5). MRC5 cells were treated with 
A549 cell derived-MV produced significantly high level of myofibroblasts 
marker alpha-smooth muscle actin (α-SMA) cytoskeleton protein and FGF. 
MVs were isolated from the myofibroblasts were enriched with α-SMA 
protein. Primary fibroblasts were treated with MVs released myofibroblasts 
expressed high level of α-MSA protein. Elements present in the CGM cause 
13 
 
aggregation of cancer cell MVs and significantly reduced the effects of MVs 
on the target cells. 
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1. Introduction 
1.1 How MVs are formed 
The mammalian body is made up of a complex collection of cells, whose 
interactions are important in term of homeostasis (1). Our understanding of 
the mechanism of cellular communication supports the discovery of  
microvesicles (MVs) as a pathway for the exchange of information between 
cells (1,2). MVs are cell membrane fragments released constitutively and 
upon activation from almost all mammalian cell types into their extracellular 
environment and into body fluids (1-3). MVs were first described by 
Chargaff and West in 1946 as a perceptible factor in plasma platelets with 
the capacity to produce thrombin (4). In 1967 they were described by Peter 
Wolf as platelet dust. These vesicles are composed of phospholipid bilayer, 
and are formed by regulated release through budding of the plasma 
membrane (5). Cells in their normal physiological states generally shed 
lower numbers of MVs than cancer cells. Cells under stressed condition, 
such as in malignancies and during hypoxia, have been shown to secret not 
only considerably higher numbers of MVs, but also MVs that are  more 
heterogeneous in size compared to their normal counterparts (6). The 
release of MVs is induced by cell surface receptor activation, increased  
intracellular Ca2+ and apoptosis. Based on electron microscopy their sizes 
vary from 0.1 to 1 µm in diameter. Their contents reflect the phenotype and 
physiological state of the parent cells and allow the identification of the 
origin of the MV. A biochemical understanding in terms of the specific lipid 
composition is essential in order to understanding the mechanism of MV 
release from the parent cells. Aminophospholipids (Phosphatidylserine and 
Introduction 
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Phosphatidylethanolamine) are specifically localised in the inner leaflet of 
the lipid bilayer whereas Phosphatidylcoline and Sphingomyeline are 
present in the outer leaflet. It is generally believed that, there are three 
major proteins which play as important role in the regulation of lipid 
distribution in the plasma membrane namelyflippase, floppase and 
scramblase.  
1.1.1 Flippase 
Flippase is responsible for the translocation of aminophospholipid (PS and 
PE) from the outer layer of the plasma membrane to the inner monolayer of 
all mammalian cells. This lipid transporter protein can be ATP dependent or 
ATP independent and it can also be selective or non-selective. The newly 
synthesized PS and PE are however, moved to the cytoplasmic face of the 
membrane by an ATP dependent flippase protein (7).  
 
1.1.2 Floppase 
Floppase is another lipid transporter protein responsible for the mobilisation 
of substrates such as lipid (Phosphatidylcoli ne and Sphingomyeline) from 
the cytoplasmic to extracellular face of the plasma (Fig.1). This class of 
transporter also consumes ATP to pump lipid outwards against a 
concentration gradient (8). Cytoplasmic Ca2+ concentration is partially 
involved in floppase activity and its activation concomitantly inhibits the 
function of flippase. 
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This lipid transporter is responsible for the degradation of transbilayer 
phospholipid gradients. In the lipid bilayer, scramblase transports lipids 
bidirectionally (7). There are three types of scramblase activity in this lipid 
transporter and two of them participate in a lipid dissipation gradient in 
membrane bilayer. The third scramblase activity depends on Ca2+ 
stimulation, and once activated results in PS being scrambled from the 
inner to outer leaflet of the lipid bilayer in eukaryotic cells (8). 
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Figure 1 Flippase, Floppase and sramblase maintain lipid asymmetry in plasma 
membrane. 
Fig.1 shows the action of lipid transporter protein in mammalian plasma cell membrane.  
PC and SM are restricted to the outer monolayer. PS and PE are localised on the 
cytoplasmic face of the plasma membrane. (A)  The distribution of PS is maintained to the 
inner membrane by an inward directing action of the flippase protein. (B) PC is localised 
to the outer membrane which organised by an outward actin floppase.  (C) Non-specific 
scramblase action in activated cells is caused by Ca2+ induction that leads to randomised 
PL distribution across the cell membrane. 
  
ATP ATP Ca
2+ 
PS 
Out 
In 
PC, cholesterol 
PC, SM 
PS, PE 
PL 
A B C 
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Increased cytosolic Ca2+ concentration causes the collapse of membrane 
asymmetry by the action of floppase and scramblase which consequently 
down regulates the action of flippase. Translocation of PS from inner to 
outer biogenic membrane is one of the prominent changes that take  place 
in the distribution of lipid in the plasma membrane of activated cells which is 
followed by the release of MVs. Therefore, the budding of these submicron 
particles from their parent cell membrane is due to the remodelling of the 
lipid bilayer and loss of phospholipid asymmetry (Fig.2) (9). After secretion, 
MVs can move within the extracellular environment and either be taken up 
by neighbouring cells or travel through body fluids for cargo delivery into 
recipient cells at distant sites (Fig.2) (10). MVs can be detected in blood 
(serum and plasma), urine, milk, sweat, saliva, ascites fluid, and cerebral 
spinal fluid (CSF) (11). 
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Figure 2 MVs bud off the plasma membrane into the extracellular environment. 
This process captures the cytosolic contents of the parent cells in the newly formed 
lumen and plasma membrane receptors in the surrounding membrane.  The membrane 
bilayer of newly formed MVs has the same specific lipid composition as their parent cells. 
This well structured membrane is characterised by the transverse distribution of lipids 
and proteins between the inner and outer leaflets. Apart from this transverse distribution, 
a lateral organisation of so-called rafts also participates in the characterisation of the MV 
membrane. In the case of MV release, a general redistribution of lipid organisation takes 
place which leads to the raft structuration, PS externalization and MV release. 
 
 
  
Activation 
Cytoplasmic 
protrusions 
0.1-1µm 
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1.2 Heterogeneity of MVs 
Human cells produce a heterogeneous population of MVs which differs 
from apoptotic bodies and exosomes in terms of size and morphology. MVs 
are larger than exosomes (50 to100 nm in diameter), their sizes ranging 
from 0.1 to1µm in diameter (12). There is a great deal of evidence in the 
literature suggesting that they are ubiquitously released mainly by cancer 
cells and other cells upon activation. The amounts of MVs are released by 
tumour cells increase considerably in aggressive types of cancer cells (13). 
While the number and composition of MVs released from normal cells are 
significantly different from cancer cells, it is still unclear whether cancer cell-
derived MVs are similar in terms of structure, composition and function.  In 
terms of size profile of MVs, researchers have used size bead-based FACS 
analysis as the primary means of MV characterization (14). However, 
isolation of MVs may easily result in an overlap at the upper end of the size 
range with apoptotic bodies and at the lower end with exosomes. Recent 
advances in capture and sorting capabilities may overcome these 
challenges (15). Another way to design more precise capture strategies is 
to establish a molecular profile of shed MV populations (16). 
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1.3 Size determination method of MVs 
1.3.1 Pre-analytical argument 
There are concerns about the pre-analytical changes of MVs in the 
diagnostic field. These changes are in terms of numbers which increase in 
response to shear stress and storage (17). Freeze-thaw cycles of MVs 
cause a substantial increase in the count of Annexin V labelled MVs by 
standard FACs analysis (18). It has also been shown that MV counts are 
altered significantly with storage time and by temperature. The type of 
buffer used to dilute the MVs can also change the MV count which shows 
the particles to be highly sensitive to environmental factors (19). MV 
analysis in terms of numbers, using standard FACS, therefore needs be 
considered in the routine diagnostic approach. 
 
1.3.2 Determination of MVs by Transmission Electron Microscopy 
The gold standard for size determination of MVs is transmission electron 
microscopy (20). However in this method, prior to analysis, the MVs need to 
be concentrated using high speed centrifugation, dehydration and fixation, 
leading to the possibility that these processes may in fact change the size 
and morphology of MVs (21). Advanced techniques such as cryo-EM 
demonstrated that the cup-shaped feature of exosomes is an artefact, due 
to the fixation and dehydration of MVs for EM. Transmission electron 
microscopy however, is the only technique so far that can simultaneously 
examine the size and structure of MVs (20). 
Introduction 
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1.3.3 Flow Cytometric detection of MVs 
FACS is a standard method for MV detection and many researchers report 
that MV counts closely correlate with varieties of physiological and 
pathological conditions (22). A standard FACS can detect MVs above the 
size of 0.2 µm. This could be a major concern in terms of MV counts 
because smaller MVs (<0.2µm) cannot be analyzed and characterized 
directly by this method. Based on FACS analysis, Annexin V is used as a 
common marker for MVs, but there is evidence for example suggesting that 
more than 80 % of platelet-derived MVs are negative for Annexin V MVs. In 
fact, Annexin V requires around 1.5 mM Ca2+ to bind the PS contents of 
MVs. Therefore If PBS is used as a diluent for MVs, it is not suitable for 
Annexin V staining of MVs, because it can interfere with the binding 
capacity of Annexin V, Ca2+ precipitating with phosphate (7). 
 
1.4 Structure of MVs 
For a long period It has been known that MVs are released from a wide 
range of mammalian cell types such as epithelial cells, endothelial, 
neuronal and blood cells (23). These vesicles have the same phospholipid 
bilayer leaflet structures as the donor cells but harbour a variety of glycol 
phospholipids, miRNA and mRNA and their composition depends on the 
cell types from which they are derived. The major challenge is to establish a 
specific method to isolate different MVs according to their composition and 
origin (24). The content of MVs originates from the cytoplasm, cytoskeleton, 
proteasome, plasma membrane, mitochondria and endoplasmic reticulum 
Introduction 
 
25 
 
(25). Furthermore, the possibility of MVs carrying transcription factors could 
enable them to serve as genotypic biomarkers to the target cells (26).  
 
1. 5 MVs and horizontal transfer of bioactive molecules  
Importantly, MV release is not a random process, such as degradation of 
plasma membranes undergoing necrosis.  In recent years, it has been 
widely accepted that miRNAs act as a major player in information transfer 
between cells (27). These RNA molecules in fact are very unstable inside 
the blood circulation. Therefore, a secure systemic delivery is required to 
prevent their degradation before reaching target cells.  All bioactive 
molecules are systematically transferred from donor to recipient cells 
through MVs and thereby protected from degradation (28) (Fig.3) and a key 
function of MVs is the transportation of RNA in cancer invasion and 
metastasis which takes place in almost all types of cancer including 
colorectal adenocarcinoma, pancreatic adenocarcinoma, lung carcinoma, 
and glioblastoma (29).   
 
1.6 Proteases in MVs 
Cancer cells of epithelial origin specifically breast carcinoma and ovarian 
cancer secrete MVs into the microenvironment carrying MMP9 and MMP2 
(30).These MVs interact with extracellular matrix causing matrix 
degradation. There are some interacting factors in fact playing a role 
between released MVs and recipient matrix such as β1 integrins. Thus, 
cancer cells release MVs as a mechanism to facilitate proteolysis at distal 
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sites creating paths for local invasion and metastasis (31). It could be 
suggested therefore that MV shedding selectively occurs at specific sites on 
the plasma membrane and is designed to release selected cellular 
components and matrix degradation.  
 
1.7 MV Interaction with target cells 
The role of MVs as intercellular communicative vectors in maintaining 
normal body homeostasis is principally due to their ability to release and to 
deliver their cargo to recipient cells. The cellular and molecular basis of MV 
targeting cells is sti ll not fully understood but mechanisms are beginning to 
be elucidated (31). The specificity of these target cells for binding of MVs is 
likely to be determined by adhesion molecules. Therefore, interactions of 
MVs with the target cells are established through specific molecules such 
as surface receptors and adhesion molecules, for example integrins which 
are present at the surface of MVs (32,33). After binding to the recipient cells,  
MVs either fuse with the plasma membrane or are internalized through 
specific endocytic pathways. In some cases MVs are stably associated with 
the plasma membrane or remain dissociated from the target cells (17). 
There are some factors which can probably interfere or even block this 
interaction of MVs with the target cells and such interference can be due to 
the translocation of PS to the outer leaflet of MVs during their biogenesis. 
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Figure 3 Types of bioactive molecules carried by MVs 
Mammalian cells are exposed to a variety of stimulations that lead to the release of MVs. 
These MVs highjack phospholipid membrane constituents and functional proteins from 
the cytoplasm of the parent cells and these bioactive molecules have significant roles in 
intercellular communication. Furthermore, under normal conditions they participate in 
homeostasis or in the case of pathology by carrying pathogenic constituents, these MVs 
therefore cause disease progression. The nature of MV cargo depends on the cell type, 
and also the state of cells. 
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1.8 MVs as diagnostic tools 
MVs influence the behaviour of target cells in a variety of ways and this is 
due to the variety of cargoes they de liver to the target cells (34). This 
ubiquitous formation of MVs enables the clinician to establish their 
diagnostic value in various pathological conditions. Much research is being 
invested in developing MVs as diagnostic tools. This is due to the 
accessibility of MVs through a variety of biological fluids such as blood, 
urine, ascites and saliva (35).  MV levels are elevated in the plasma of 
individuals suffering from acute and chronic vascular diseases such as 
acute coronary syndrome, hypertension renal failure and pulmonary 
diseases (36), and  many studies have implicated MVs as biomarkers for 
cancer diagnosis, demonstrating that the level of MVs in blood positively 
correlates with cancer prognosis. Patients suffering from glioblastoma for 
example, have high numbers of MVs in their blood which carry significant 
levels of mRNA, thus making them useful markers for the diagnosis of 
cancer (37). 
 
1.8.1 MVs as therapeutic delivery vehicles 
MVs have the capacity to modulate the phenotype of target cells. This 
effect is due to the diverse RNA species they carry and transfer into target 
cells (21). Recent studies have shown that stem cell-derived MVs can 
mimic stem cell function, therefore playing a relevant role as mediators of 
stem cell induced regeneration of injured cells and tissues (38). MVs can 
securely transfer miRNA into the target cells which cause epigenetic 
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changes in the recipient cells. Furthermore, the mRNA content of MVs may 
be delivered to recipient cells and translate to a functional protein in the 
target cells. Endothelial progenitor cells derived MVs for example are able 
to establish new vascularisation and muscle regeneration in hind limb 
ischaemia (38,39). However, the biological effects of MVs on the target 
cells can be altered by the functional state of the recipient cells. In fact, the 
effect of miRNA delivery into the target cells will also be dependent on 
which pathways are activated in the case of normal or inflammatory states 
and malignancy (38-40).  
 
1.9 Normal function of MVs 
Overall, there is not enough information about the functions of MVs in 
normal development. For example, the number of MVs detected in the 
peripheral circulation of women during pregnancy is higher than non-
pregnant woman but the actual function of MVs is sti ll not fully understood 
during pregnancy. However, some functional proteins such as β-Catenin 
are detected in the isolated MVs. It is generally believed that this protein 
plays central roles in tissue and organ development (41). Other functional 
proteins that can be detected in MVs during pregnancy are sonic hedgehog. 
This protein has critical functions in embryogenesis including nerve system 
development and the gastrointestinal system (42). MVs which are present 
in bronchoalveolar fluid may increase the secretion of proinflammatory 
cytokines from the epithelial cells of airways. The presence of MVs in the 
upper respiratory tract can function as tolerized molecules when exposed to 
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some kind of allergens (43). Within the neuronal system, MVs are secreted 
from neurons, oligodendroglial and microglia l cells which can participate in 
myelin formation, neurite outgrowth and neuronal survival (44).  
 
1.10 Pathological functions of MV 
Levels of MVs in body fluid are raised in a range of  pathological conditions 
(45). Patients suffering from thrombotic diseases such as cardiovascular 
and cerebrovascular diseases, for example, have high numbers of platelet 
derived MVs in their peripheral blood (46).  It is not entirely clear how MVs 
can contribute to the pathogenesis of these diseases, but some previous 
work supports the idea of MV participation in the activation of the 
coagulation cascade through the presence of phosphatidyl serine. Patients 
suffering from chronic inflammation such as rheumatoid arthritis show high 
numbers of MVs in their body fluids. In this case the presence of MVs in 
body fluids confirms the function of MVs as chemoattractant molecules and 
inflammatory mediators (47). Cancer cells secrete an increased number of 
MVs which can be detected in a variety of human cancers including 
prostate and ovarian cancers. The role of MVs in human malignancies is 
thought to involve the progression of the diseases and metastasis of cancer 
cells to distal sites (48). 
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1.10.1 MV participation in inflammation 
Inflammation is collectively established as a result of the interaction 
between various cell types. This communication takes place either directly 
between cells or through the mediation of cytokines and other soluble 
factors. MVs are released by those cells that actively participate in the 
inflammatory process (49). The role of such inflammatory MVs is generally 
dependent on the stages of inflammation. In the early stage, cells in the 
immune system especially neutrophils shed high numbers of MVs which 
cause activation of macrophages. Activation of macrophages i n this stage 
of inflammation is accompanied by the release of anti-inflammatory 
mediators such as TGF β1 and IL 10 (50). At the later stage of inflammation, 
MVs released from the immune cells strengthen the inflammatory response. 
These functions of MVs are fulfilled by the transfer of chemokine receptors 
such as chemokine receptor4 and chemokine receptor 5 which stimulate 
the release of IL6 and monocyte chemotactic protein (51).   
 
1.10.2 Immunomodulatory functions of MVs 
Cancer cells release MVs to promote cancer progression, as shedding MVs 
suppress anti-tumour responses to significant levels. This function of MVs 
is caused by modulation in signalling pathways which are responsible for T- 
cell proliferation and activation (52). These suppressive effects of MVs in 
the tumour microenvironment are due to the presence of membrane-bound 
transforming growth factor beta, CD 73, Fas ligand and galectins.  MVs 
derived from mammary tumours carrying interleukin inhibit the 
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differentiation of bone marrow precursors in dendritic cells (53). Cancer cell 
derived MVs are suggested to suppress the response of immune cells by 
preventing leukocyte adhesion to tumour necrosis factor alpha-(TNF-α) 
activated endothelial cells. This immune suppressive function of MVs is due 
the membrane bound intra cellular adhesion molecules -1 (ICAM-1) (54). 
 
1.10.3 MVs and tumour growth 
The number of MVs derived from cancer patients is significantly higher than 
that of healthy individuals (55); this elevation correlates with poor prognosis. 
However, not all MVs found in body fluids are secreted by cancer cells, the 
vast majority of these MVs being shed by activated platelets, lymphocytes, 
macrophages and erythrocytes (56). Recently, a large scale proteomic 
analysis was carried out to determine the differences between protein 
content of MVs from healthy and neoplastic patients (57). The majority of 
proteins in tumour derived MVs are known to be linked with cancer 
development and cancer progression, and these proteins include 
oncoproteins, oncogenes and chemokine receptors as well as soluble 
factors (58). Tumour-derived MVs participate in cancer growth by 
transferring oncogenic molecules to other cells in the tumour 
microenvironment at specific distal sites. Some caution is required when 
interpreting the results, however, because MV purification techniques and 
contamination of samples will change the consistency and reproducibility of 
data (59).  
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1.10.4 MVs and angiogenesis 
MVs shedding from malignant cancer cells especially from glioblastomas 
carry high concentrations of angiogenic factors such as vascular endothelial 
growth factor, Interleukin8, interleukin 6 and tissue inhibitor of matrix 
metalloproteinase-1 (60). Another angiogenic cascade protein found 
recently in cancer derived MVs is delta like 4 Zigland (D 114) (61). This 
protein can block the Notch signalling pathway thereby increasing vessel 
density in the tumour microenvironment. Other components of MVs 
participate in angiogenesis and include sphingomyeline and matrix 
metalloprotease inducers (62).  
 
1.10.5 MVs and phenotypic changes of target cells  
The capacity of individual cells to acquire phenotypical changes has been 
clearly demonstrated by exchanging genetic material between donor and 
recipient cells (63). Mammalian cells use MVs as a mechanism to deliver 
the genetic composition safely and securely to the recipient cells . When 
MVs are taken up by recipient cells, they can profoundly change their 
biology. These changes can be either transitional or permanent. These 
phenotypic changes are due to the effect of the contents of MVs on the 
target cells (64). Microvesicle cargo includes membrane proteins, cytosolic 
proteins, nucleic acids and membrane lipids that are deli vered into the 
recipient cells (57), which interfere with the physiological function of the 
recipient cells. 
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1.10.5.1 Epithelial to Mesenchymal Transition 
There is evidence in the literature suggesting the role of cancer cell derived 
MVs in bringing about phenotypic changes of recipient cells (65). The 
epithelial to mesenchymal transition (EMT) is an embryonic cell 
transformation that occurs in almost all normal mammalian tissues (66). In 
this process epithelial cells lose their polarities by down regulating the 
expression of cell adhesion molecules such as E-cadherin (67). The 
decrease in the epithelial gene expression is accompanied by increase in 
mesenchymal genes such as Vimentin and fibronectin (68). EMT is a 
reversible biological process that allows epithelial cells which normally 
interact with their basement membrane by their basal surface, to undergo 
multiple biochemical changes that enable them to acquire mesenchymal 
characteristics (69). Several rounds of EMT and mesenchymal to epithelial 
transition (MET) are required for primary cells in order to become fully 
differentiated, specialized cell types. It is one of the most important changes 
that happens during development and disease progression (70). Epithelial 
to mesenchymal transition is triggered by a variety of extracellular signals. 
Generally, EMT is involved in major physiological and pathological changes 
including morphogenesis, fibrosis and tumour progression and metastasis 
(71). 
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1.10.6 Types of Epithelial to Mesenchymal Transition 
1.10.6.1 Morphogenetic Epithelial to Mesenchymal Transition (Type 1) 
Morphogenetic EMT is linked to embryogenesis when the primary 
mesenchymal tissues are formed from the upper epiblast epithelium which 
results in a three layered blastocyst, (ectoderm, mesoderm, and endoderm) 
(72). Epithelial cells undergoing mensenchymal changes result in the 
formation of the ectoderm, mesoderm and   endoderm from the invaginating 
primary streak (73). Cells in the primary streak are transformed into a 
mesenchymal phenotype under the influence of the Wnt signalling pathway 
(74). Developmental epithelial to mesenchymal changes also take place 
during neurulation, started in the neural plate. This phenotypic change 
facilitates the neural tube formation and finally forms the spine and brain 
(75). Neural crest cells also acquire a mesenchymal characteristic that 
facilitates their migration and dissemination throughout the embryo. This 
transformation finally participates in the generation of tissues including the 
adrenal medulla and the peripheral nervous system (76). 
 
1.10.6.2 Fibrotic Epithelial to Mesenchymal Transition (Type 2) 
Fibrotic EMT occurs to maintain tissue homeostasis (77,78). This 
phenotypic change takes place during tissue injury and results in wound 
healing and tissue remodelling (77). The difference between morphogenetic 
and fibrotic epithelial to mesenchymal transition at the molecular level is 
that, the fibrotic type is triggered and governed by inflammatory reactions 
(79). There is much evidence to suggest that EMT takes place in 
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progressive kidney and lung disease, as a result of which functional 
epithelial cells in the kidneys are replaced by the deposition of dysfunctional 
collagens and other matrix components (80).       
 
1.10.6.3 Epithelial to Mesenchymal Transition in cancer (Type 3) 
This type of epithelial to mesenchymal transition is distinguished from its 
type 1 and type 2 counterparts in the cellular context, because in almost all 
cases it occurs in oncogenically transformed cells (81). More than 80% of 
tumours are carcinomas of epithelial origin and one of the hallmarks of  
these malignant tumours is loss of epithelial morphology and gain of 
mesenchymal characteristics (82). Cancer cells acquire this phenotypic 
change in order to infiltrate into surrounding tissue and ultimately 
metastasize to distant sites (83). It is very difficult to observe EMT in 
malignant tumours because tumours are made up of a complex collection 
of tumour cells and stroma. In cell culture models, however, this phenotypic 
change can be accurately studied. ‘’ IF’’ as part of EMT tumour cells 
increase the production of proteases, these enzymes are able to degrade 
the surrounding basement membrane (84). However, the most important 
question in terms of genetic alteration and EMT, whether the genotypic 
changes in cancer cells are due to the acquisition of phenotypic change of 
cancer or as a result of an independent phenomenon has not yet been 
answered. The migration of cancer cells takes place through the basement 
membranes of mesenchymal cells into the adjacent tissue which normally 
functions as a barrier between epithelial cell tissue and stroma (85). 
Metastatic cells gain the migratory capacity at the expense of their 
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proliferative potential (86). Therefore, a reverse conversion of 
mesenchymal epithelial transition is required for cancer cells in order for 
them to become fully functional. Mesenchymal to epithelial transition (MET) 
therefore, enables the cancer cells to produce macro-metastasic cells 
similar to the primary tumour at a distal site (87). This phenotypic change in 
cancer cells in fact, defines a key feature of malignant cells with successful 
metastatic behaviour (88). 
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Figure 4 Epithelial Mesenchymal Transition is reversible process. 
EMT is a biological process that allows epithelial cells that are normally attached to their 
basement membrane via their basal surface, to undergo multiple biochemical changes 
that enable them to acquire mesenchymal characteristics. This phenotypic change takes 
place in epithelial tissue during wound healing and malignancies. EMT takes place in 
carcinomas and leads to the progression of disease. Cancer cells use this physiological 
process for colonisation of local and distant organs. This phenotypic change is believed to 
be reversible, therefore, cancer cells using EMT to survive in blood circulation and 
lymphatic system.  Malignant cells that have undergone EMT acquire a reversible process, 
so-called MET in the secondary organ and establish secondary tumours. However, it is still 
not clear whether transformation of a benign tumour into a malignant form can actually 
represent EMT, and if so how important it is in the process of cancer progression. 
  
Introduction 
 
39 
 
1.10.7 Molecular mechanism of EMT 
The molecular processes involved in EMT include activation of transcription 
factors, expression of specific cell surface proteins, expression and 
reorganization of cytoskeletal proteins, degrading enzymes and changes in 
the expression of specific microRNAs. Assays such as loss of cell adhesion 
and cytoskeletal rearrangement are in fact used to assess the progression 
of EMT in highly metastatic cancer patients.   
 
1.10.7.1 Adherens Junction and EMT 
The major concept of EMT is the dissolution of adherens junctions that are 
derived from the interaction of E-cadherin between the epithelial cells (89). 
In principle, epithelial cells do not have the ability to dissociate from 
epithelial entities and escape to other organs or the circulatory system (90). 
This is due to the expression of junctional protein complexes including tight 
junctions, adherens junctions, desmosomes and gap junctions in epithelial 
cell lines (91). At the initial stage of EMT the reorganisation of the adherent 
junction and down regulation of E-cadherin lead to the loss of epithelial 
polarity and destroy the epithelial cell sheet which functions as a barrier 
between the epithelial and the extracellular environment (92).  
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1.10.7.2 Integrin signalling and EMT 
Integrins partially participate in cell communication within the 
microenvironment (93). The role of integrin in cell-to-cell and cell-to-matrix 
interactions is defined in term of cell adhesions, cell migration, cell 
proliferation, invasion and cell survival (94): the level of integrin increases 
significantly during EMT (95) and integrins participate in EMT by creating 
traction force that activates transforming growth factor beta  (TGF-β) (96).   
 
1.10.7.3 Intermediate filament and EMT 
Intermediate filaments are important components of the cytoskeletal 
compartment of almost all mammalian cells  (97). They are found in the cell 
cytoplasm and nucleus of cells and their functions include giving 
mechanical support to cells, tissues and organs. During EMT the 
intermediate filament network of epithelial cells is reorganised (98). This 
reorganisation causes disruption to the desmosomal structure which 
consequently leads to the release of cells from well organised epithelial 
sheets. Another strong function of intermediate fi lament subunits observed 
in almost all EMT processes is the constant suppression of cytokeratin  
expression (99). This is the major desmosome linked intermediate fi lament 
protein in cells within the epithelial cells. In the last ten years Vimentin has 
been considered as an epithelial mesenchymal marker (100). Vimentin 
expression in EMT is characteristically unregulated, and it has been 
demonstrated that knocking down this gene results in down regulation of 
EMT events in mammary epithelial cells (101). 
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1.10.7.3.1 Vimentin and prostate cancer 
The expression pattern of Vimentin in normal and malignant cells is of great 
value for cancer diagnosis and cancer progression. Vimentin expression is 
mainly detectable in the metastatic form of prostate cancer (102). Down 
regulation of this intermediate fi lament in the metastatic form of prostate 
cancer significantly decreases motility and invasiveness (103). Another 
independent study demonstrated that this protein is over expressed in 
highly aggressive types of prostate cancer (PC3-M; PC3-1E8). Over 
expression of Vimentin by and large is accompanied with the down 
regulation of the E-cadherin/ β-catenin complex (104). 
 
1.10.7.3.2 E-cadherin and prostate cancer 
Epithelial tissues are most abundant in mammalian organs and more than 
90% of malignancies arise from carcinomas of epithelial origin.  Malignancy 
is defined by the ability of cancer cells to overcome cell-cell adhesion and 
invade surrounding tissues, and E-cadherin plays a significant role in the 
maintenance of intercellular adhesion and cell polarity. In almost all types of 
epithelial cancer, the expression of this junctional protein is down regulated 
(105). This is a clear indication of the tumour suppressor effect of E-
cadherin in carcinomas of epithelial tissue. The mechanism of this inhibitory 
effect is believed to come from blockage of the EMT process. However, a 
great deal of study is required in this field to identify the molecular 
mechanism by which E-cadherin can down regulate tumorigenesis and 
cancer invasion and metastasis.  
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Figure 5 Adhesion signalling in epithelial cells. 
The signalling pathway is formed by the action of P120 and catenin activating 
Rac 1. The activation of Rac 1 is accompanied by the inhibition of Rho A. Alpha 
catenin blocks the function of Arp2/3 in actin polymerization. When the 
cadherin signalling pathway becomes activated, it disrupts the acto-myosin 
protein arrangement and decreases the cell-cell interfacial tension thus 
widening the surface contact. The mechanical tension results in the adhesion 
complex breaking away from the cytoplasmic side. However, it is not entirely 
clear yet, whether dissociation takes place inside the cells between α-actin and 
β-actin. In the case of dissociation of these cytoskeleton proteins, maintaining 
the β-actin and α-actin interaction can be achieved by the establishment of 
chemical signalling from P120-catenin.  
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1.10.7.4 Microenvironment signals an EMT 
EMT can be induced by a variety of extracellular signals both in an 
autocrine or paracrine way including extracellular matrix (collagen and 
hyaluronic acid) and secreted soluble factors such as trans forming growth 
factor beta (TGF-β), Wnt, Hedgehog, epidermal growth factor (EGF) and 
hepatocyte growth factor (HGF) (106). The most critical signalling pathways 
participating in EMT are Wnt, TGF-β, EGF, hedgehog and Notch (107). 
These signalling pathways in fact, reorganise a set of genes and protein 
networks that are needed for the establishment of the mesenchymal cell 
type (108), their activation causing disassembly of epithelial architecture 
such as cell polarity and cellular junctions (109). 
 
1.10.7.4.1 Cell polarity and EMT 
Epithelial cell polarity is governed by a group of proteins known as partition 
defective proteins which include PAR3, PAR6 aPKC and PAR1 (110). 
Partition protein 3, 6 and protein kinase C, are localized predominantly in 
the apical junction and plasma membrane of epithelial cells (111). Partition 
defective protein 1 presents at the basolateral membrane of epithelial cells 
(111). These proteins establish and maintain the apical junction of epithelial 
cells. Epithelial cells undergoing EMT lose their top–bottom polarity leading 
to a more fibroblastic phenotype (112). The interaction of these two 
complexes in the apical and basolateral junctions leads to the formation of 
cellular asymmetry in epithelial cells (113).   
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Down regulation of partition defective protein 3 can cause TGF-β to disrupt 
the apico-basal polarity and consequently induce EMT in the target cells 
(114).   
 
1.10.7.4.2 Transforming growth factor-β and EMT  
Transforming growth factor beta is the major inducer of EMT in epithelial 
cells (115). This cytokine utilizes two signalling pathways, gene expression-
dependent and gene expression-independent to induce EMT on target 
epithelial cells (116). TGF-β causes EMT not only during organ 
development but also induces EMT during inflammation and tumour 
progression (117). Knocking down of Smad 3 expression blocks TGF-β- 
induced EMT in primary epithelial cells (118). In the case of malignancy, it 
has a biphasic function in different stages of tumour development. At the 
early stage of cancer progression it inhibits tumorigenesis by induction of 
apoptosis and cell cycle arrest of target cells (119). At the late stage of 
disease, it acts as a positive modulator of tumour progression (120), the 
stimulatory function of TGF-β on cancer progression and metastasis being 
due to the induction of EMT in recipient cells (121).  
 
1.10.7.5 Gene expression- dependent mechanism 
Amongst the typical features of EMT are the loss of epithelial markers such 
as E-cadherin, Cytokeratin, Ocludin and desmoplakin and gain of 
mesenchymal markers such Vimentin, N-cadherin and fibronectin (122). 
Among these markers, loss of E-cadherin molecules is considered the 
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hallmark of EMT (123). A number of transcriptional factors are involved in 
this process. Transcription factors participating in E-cadherin repression 
during EMT include Snail, ZEB, and basic helix-loop-helix factors such 
Twist, KLF8 and Fox C2 (124). These transcriptions factor down regulate 
the expression of E-cadherin proteins by binding to the E box at the CDH1 
promoter region (125). Slug is another transcription factor that is involved in 
the down regulation of desmoplakin and plakoglobin expression. This down 
regulation in turns disassembles the junctional complex which is a 
specialized protein structure for cell-to-cell adhesion, the so-called 
desmosomes component of epithelial cells. This series of events causes 
defects in the adjoining epithelial cells and encourages the cancer cells to 
detach from primary tumour and make their way to the circulatory system. 
 
1.10.7.6 Gene expression-independent mechanism 
In the gene expression-independent mechanism, the type II TGF-β receptor 
becomes activated as a result of ligand receptor interaction (126). After it’s 
activation, it interacts with a component of the tight junction, occluding, 
which leads to the phosporylation of the Par6 protein (127). This type of 
interaction and phosphorylation recruits Smurf1 that leads to degradation of 
RhoA in a ubiquitin-dependent manner (128). RhoA is a member of the 
GTPase family responsible for the maintenance of the apico-basal polarity 
and junctional stability. Therefore, the degradation of RhoA by TGF-β in fact,  
causes loss of epithelial cell polarity which is an important factor in the EMT 
process (104).   
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1.10.7.7 Wnt/β-catinin signalling and EMT 
The β-catenin pathway is heavily involved in EMT cell remodelling (129). In 
the presence of Wnt ligands, Wnt binds to  the receptor Frizzled and 
transmembrane low density lipoprotein receptors to inactive glycogen 
synthesis kinase-3 in the ‘’destruction complex’’ (130). This causes 
stabilization of β-catenin in the cytoplasm and then it’s translocation into the 
nucleus. Accumulation of β-catenin in the nucleus follows and it’s binding to 
the enhancer binding factor leads to the transcription of the target genes 
(131). Genes participating in EMT signalling pathway include c- myc, cyclin 
D, surviving and slug. The genetic alteration that is caused by the activation 
of the Wnt signalling pathway in particular leads to the reorganization of the 
cytoskeleton of epithelial cells (132,133). 
 
 
1.10.8 EMT generates cells with stem cell-like properties 
There is a group of transcription factors that become activated at the very 
early stages of life by coordinating EMT for new organ formation and 
development (134). These embryonic transcription factors are believed to 
become activated in the later stage of human life by participating in the 
formation of malignant traits such as, resistance to apoptosis, motility, and 
invasiveness of the cancerous cells (135). During EMT, epithelial cells gain 
a self-renewal capacity, which is the unique feature of stem cells (136). This 
process in fact, is similar to the stage that takes place during tissue repair 
and regeneration.  At this stage the adult stem cells move out from the 
bone marrow and enter the circulation and reach their final destination 
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where they start a new phase of proliferation and differentiation to 
participate in tissue restructuring (135). 
 
1.10.9 EMT and drug resistance 
Drug resistance is a major concern in the medical field that results when 
diseases no longer respond to pharmaceutical treatment. The method of 
drug resistance can be specific or evolutionarily conserved. Many types of 
disease including cancer are susceptible to treatment to begin with but over 
time develop resistance. Overall, there are two specific mechanisms by 
which diseases can resist pharmaceutical treatment and these include DNA 
mutations and metabolic changes which cause drug inhibition and 
degradation. The role of neoplastic EMT in drug resistance is a new 
phenomenon in oncology (137). One reason cancer cells acquire 
mesenchymal characteristics is to survive intravasation and adopt a new 
environment during metastasis.  Malignant cells use this phenotypic change 
as a mechanism against chemotherapy. There are many factors during 
EMT that can participate in the development of drug resistance (138), for 
example to chemotherapy. For example, TGF-β can also generate survival 
signals for neoplastic cells against chemotherapy (139). However, the level 
of drug resistance in cancer cells is determined by the stage of the tumour, 
and the grade of tumour is measured by the degree of EMT within the 
neoplastic tissue. 
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1.10.10 EMT and apoptotic regulation 
Apoptosis or programmed cell death in multicellular animals is governed by 
the balanced expression of pro-apoptotic and anti-apoptotic proteins. 
Normal cell regulation is maintained by a balance between cell growth and 
cell death. Carcinomas of epithelial origin acquire phenotypic changes to 
develop resistance to chemotherapy, one of the mechanisms being due to 
the expression of anti-apoptotic proteins such as those of the Bcl-2 family. 
In a model of EMT breast epithelial cell lines were found to display stem 
cell-like characteristics with enhanced metastasis and secondary tumour 
formation. When these mesenchymal-like cells were exposed to apoptotic 
inducers, they produced a very poor response against the cytotoxic drug 
(135). This research group later found that, the expression of anti-apoptotic 
protein (Bcl-xL) was high in the breast epithelial cells lines that had 
undergone EMT compared to the epithelial cells under basal conditions. 
Importantly, by knocking down Bcl-xL expression in transformed cells, 
apoptotic resistance was eliminated. 
Therefore, cancer cells acquire EMT as a mechanism for cell survival and 
motility. One of the mechanisms by which in fact cancer cells acquire 
resistance is thought to be through the EMT process by disrupting 
programmed cell death and by over expression of anti-apoptotic proteins 
(140).      
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1.10.11 EMT and ECM regulation 
Extracellular matrix (ECM) is the major component in the tissue 
microenvironment and in the case of epithelial tumours, around 60 % of the 
solid tumour is composed of stroma. ECM remodelling by cancer cells can 
in fact facilitate tumour progression, local invasion and metastasis. 
Epithelial cells are separated from mesenchymal counterparts by a 
specialized connective tissue in the ECM called the basement membrane, 
and the phenotypic characteristic of epithelial cells is governed by this layer 
of connective tissue. In order for a carcinoma in situ to establish a 
relationship with ECM, tumour cells need to cross this  barrier of basement 
membrane.  
Therefore, cancer cells acquire EMT in order to  firstly remove the partition 
which is located between epithelial and mesenchym and secondly, to 
orchestrate the remodelling of the ECM. After the dissolution of the 
basement membrane, cancer cells exposed to the ECM component present 
in the mesenchymal compartment.  This exposure causes further reduction 
of epithelial function. Therefore, malignant cells undergoing EMT are 
capable of expressing high amount of MMPs (141), which are the major 
modulators of the tumour microenvironment. The major MMP subtypes 
include, collagenases (MMP-1, MMP-8, MMP-13), Gelatinases (MMP-2, 
MMP-9), Matrylisins (MMP-8, MMP-26), membrane type MMPs (MMP-14, 
MMP-15, MMP-16, MMP-17, MMP-24, MMP-25) and stromelysins (MMP-3, 
MMP-10, MMP 11), MMP-1, MMP-7 and MMP-9 being important in the 
development of epithelial carcinomas (142). 
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1.10.12 EMT and cell cycle regulation 
Normal tissue morphology and function in the human body is maintained by 
a strict number of cells. This strict limitation of cells can only be achieved 
through a well governed regulation of the cell cycle. In mammals the cell 
cycle is believed to be regulated by a complex network which is not yet fully 
defined.  There are a number of cell cycle related genes which are thought 
to participate in cell cycle progression. These complex networks include 
cyclins, cyclin-dependent kinases and histone modification enzymes such 
as histone deacetylases (HDACs) (143). Although cell cycle state is 
considered one of the most significant factors for cellular response to 
extracellular stimuli, very little attention is paid to the cellular responses 
generated during EMT. It is generally accepted that growth arrest is a step 
that can be defined by cell cycle regulation and that it is required for cells 
undergoing differentiation. For example, TGF-β induces EMT in epithelial 
tissues by arresting target cells in the G1/S phases of the cell cycle. This 
cell cycle arrest in fact, could explain one of the mechanisms by which 
cancer cells develop resistance to chemotherapy and bypass  apoptosis. 
Indeed, cells undergoing EMT acquire resistance against apoptosis in fatal 
rat hepatocytes (144).  
Although there is an obvious relationship between the cell cycle regulation 
and cellular transformation, there is little knowledge about the cellular 
changes which influence the cell cycle dependent EMT. 
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1.11.1 Carcinoma cell derived MVs and tumour microenvironment 
It is generally believed that almost all cells in normal tissues communicate 
with each other through complex interactions such as direct contact or 
indirectly by soluble or insoluble biochemical molecules (145). Over the last 
decade, scientists have proved that one of the most important roles of MVs 
is to establish communication between cells in different organs. In 
pathological conditions ‘however’ the normal interaction between cells in 
the microenvironment becomes disrupted. In the case of inflammatory 
conditions or malignancy for example, up-regulation of degrading enzymes 
such as MMPs by stromal cells and expression of cytokines and 
chemokines by immune cells cause major changes in ECM. In the case of 
carcinoma, a complex proliferative signalling network is established 
between the cancer cells, stromal cells and the immune cells, such that the 
tumour microenvironment is made of a collection of cancer cells, stroma 
cells, fibroblasts, endothelial cells, adipocytes and immune cells  (146). 
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1.11.2 Cell components of ECM 
1.11.2.1 Tumour Associated Macrophages (TAMs) 
Macrophages encompass the major portion of the leukocyte population and 
their role in innate and adaptive immunity have been known for over 
century, but their involvement in the biology of cancer are recognised 
recently (147). TAMs are heterogeneous population of stromal cells in the 
tumour microenvironment and the role of TAMs in tumour progression is 
complex. Although these activated immune cells are supposed to have anti-
tumour activities, according to the literature, their anti-tumour activity is 
evaded by  cancer cells (148). Macrophage infiltration in the tumour site in 
fact is accompanied with tumour vascularity and invasiveness. The 
recruitment of TAM is mediated by a group of chemoattractants, such as 
monocytechemoattractant protein 1(MCP- 1/ CCL2), macrophage 
inflammatory protein-1α (MIP-1α/ CCL3), and the infiltration of 
macrophages to the tumour site is accompanied by increases in tumour 
vascularity and invasiveness (149). However, accurate identification of 
TAMs are not an easy task when the plasticity of these cells population are 
considered and the lack of unique surface markers between the lineages 
has made it difficult to pinpoint which myeloid cell population have been 
studied (150). Making the matter more complicated is the fact that most of 
our the knowledge about myeloid cell phenotypes in tumour is derived from 
animal studies; trans-species differences in the expression of certain 
marker have made the direct translation of human cancer difficult (151). 
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1.11.2.1.1 TAMs and tumour growth 
TAMs are the main regulators of carcinogenesis in epithelial tumours. The 
origin of TAMs is either from resident tissue or they are attracted from the 
bone marrow or spleen (152). Their role is demonstrated at the leading 
edge of the tumour which drives the invasive cellular phenotypes (153), and 
their participation in cancer invasion is due to tumour derived colony 
stimulating factor-1 (CSF-1) and macrophage derived EGF. Furthermore, 
TAMs are demonstrated to be the major source of proteases such as 
cysteine cathepsins, enzymes that have strong pro-tumorigenic activities 
and that also result in resistance against chemotherapy (153). 
1.11.2.2 Fibroblast cells 
Fibroblasts are a heterogeneous population of mesenchymal cells. From a 
morphological point of view, these stromal cells are characterized by their 
spindle shape and oval nuclei. The main function of these mesenchymal 
cells is the synthesis and deposition of collagen and in maintaining 
homeostasis of adjacent cells (154). This function of fibroblasts is mainly 
fulfilled by their proliferation, differentiation and production of collagen and 
MMPs. They can also respond to growth factors, cytokines and chemokines 
and consequently orchestrate the remodelling of ECM and they are main 
contributors of angiogenesis in almost all tissues (154). Tumour associated 
fibroblasts are stromal cells in the tumour microenvironment but differ 
morphologically from the fibroblasts in normal adjacent tissue.   
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1.11.2.3 Fibroblast differentiation 
Fibroblast differentiation is considered to have an important role in tissue 
remodelling and cancer progression and metastasis. The activation of 
fibroblasts is mostly regulated by certain mediators such as growth factors 
and cytokines that are released by cancer cells. TGF-β is recognised to be 
one of the central inducers of fibroblast differentiation causing the 
expression of cytoplasmic alpha Smooth Muscle Actin (α-SMA) 
cytoskeleton protein (155). Alpha-SMA is widely used as a molecular 
marker for the determination of fibroblast differentiation. 
The physiological function of fibroblasts is the synthesis of collagen, and 
once this mesenchymal cell has transformed to a myofibroblast, it can 
participate in the production of proteases, pro-angiogenic factors and pro-
metastatic molecules. Excessive production of α-SMA interferes with the 
normal physiological functions of target organs and remodelling of ECM 
(156). There are some other novel markers and modulators such as 
endosialin in cancer associated fibroblasts and P311 in hypertrophic 
myofibroblasts during wound healing which are used to assess 
myofibroblast differentiation (157).  
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Figure 6 Schematic diagram of fibroblast differentiation. 
(A) Normal fibroblast cells surrounded with ECM.  Fibroblast cells exhibit mesenchymal 
characteristics with front–back polarity and an oval shaped nucleus. At the molecular 
level, a fibroblast cell is characterized by the cytoplasmic expression of a mesenchymal 
marker, the intermediate filament protein Vimentin. (B) Shows the activated form of a 
fibroblast cell, the so-called myofibroblast.  Myofibroblast cells differ from fibroblasts in 
terms of morphology, myofibroblast cells looking star shaped compared to fibroblasts 
that look elongated. At the molecular level, myofibroblast cells are recognised by the 
expression of cytoplasmic α-SMA cytoskeleton protein. There are a range of growth factor 
proteins and cytokines which cause activation of fibroblasts to myofibroblasts. 
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1.11.2.4 Tumour associated fibroblasts or Myofibroblasts 
Myofibroblasts are intermediate cells between fibroblasts and smooth 
muscle cells that can generally be found in fibrotic tissues and solid 
tumours. Myofibroblasts are characterised by the expression of α-SMA 
cytoskeleton protein which is used as a reliable marker for these activated 
stromal myofibroblast cells (158). However, there is some evidence 
suggesting that myofibroblasts are presents in normal tissues such as 
alveolar septa and bone marrow stroma (159). 
 
1.11.2.4.1 Biology of myofibriblasts 
Myofibroblasts are the most prominent cell type in the tumour micro-
environment, and in the context of epithelial carcinoma, myofibroblasts are 
referred to as tumour associated fibroblasts. The biological characteristics 
of myofibroblasts have been well defined in the last decade and significant 
improvements have been made regarding their participation in physiological 
and pathological environments. In breast, prostate, and pancreatic 
carcinoma for example, these specialised cells correlate with malignancy 
grade and poor prognosis. 
However, despite much research on the biological features of 
myofibroblasts, there are many questions yet to be answered  (160); what  
are the progenitor cells of myofibroblasts?; how is the contractile activity of 
myofibroblasts regulated?; is the α-SMA cytoskeleton protein a specific 
marker for the recognition of myofibroblasts? 
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1.11.2.5 Myofibroblast inducers 
1.11.2.5.1 TGF-β induces fibroblast activation 
Mammals have three different forms of TGF-β (TGF-β 1, β2 and β3). Each 
of these cytokines is expressed widely throughout the body (161). When 
tissue homeostasis breaks down, TGF-β is believed to act as a pro-fibrotic 
cytokine which causes proliferation and differentiation of fibroblasts into 
myofibroblasts, fibroblast activation leading to the over expression of ECM 
and α-SMA cytoskeleton protein. However, endogenous expression of 
TGF-β under normal conditions is sufficient to increase the function of this 
cytokine (162). 
 
1.11.2.5.2 Connective Tissue Growth Factor (CTGF) 
CTGF is a member of the extracellular signalling protein family which is 
characterised by a high content of cysteine amino acid residues (163). 
CTGF induces fibroblast differentiation either by directly binding to the 
target fibroblast cells or indirectly acting on other mediators to interact with 
their receptors on the fibroblasts (164). CTGF is shown to stimulate lung 
fibroblast cells which lead to proliferation and a high level of expression of 
proteins, including, type 1 collagen, cytoskeleton protein vinculin, moesin, 
ezrin and IQ motif containing GTPase activating protein 1(IQGTAP1), a 
scaffolding protein; the cytoskeleton protein that is elevated in stimulated 
lung fibroblasts participates in cell migration (165). 
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1.11.2.5.3 FGF as inducer of fibroblast differentiation 
The FGFs are a polypeptide growth factor family composed of 22 
structurally similar ligands and found in all mammalian cells (166). FGF 
activities are mediated through the activation receptor tyrosine kinases. The 
signalling stimulated by these regulates cell proliferation, differentiation, and 
migration of almost all mammalian cells from embryogenesis to adult life 
(166). Many scientists believe that apart from its role in myofibroblast 
differentiation, it is largely expressed by cancer cells as an autocrine growth 
factor which provides self-sufficiency in growth signals (167). 
 
1.11.2.6 Myofibroblast response to tumour cells 
There is much evidence that myofibroblats participate in the multistep 
processing of tumorigenesis. The pro-tumorigenic activities of 
myofibroblasts are due to their direct influence on cancer proliferation, 
differentiation, invasion and metastasis. Myofibroblasts are believed to pave 
the way for cancer cells to invade neighbouring tissues (168). Cancer cells 
can use the myofibroblast as a vehicle to invade the tissue 
microenvironment. Furthermore, myofibroblasts can be used as a 
prognostic tool to assess tumour grade and provide information about 
response to anti-cancer therapy. However, there is still no concrete 
evidence to prove whether myofibroblasts are capable by themselves of 
inducing malignant cell transformation (169). One important question yet to 
be answered is: since neither the cancer nor the myfibroblasts are normal, 
how and where does the pathology begin?  
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1.11.2.7 Tumour angiogenesis 
Malignant cells utilise more energy than normal tissues, this being due to 
the high level of activity of cancer cells in the tumour microenvironment. 
Biopsies of the solid tumour always emphasise the abundance of vascular 
structure. However, these blood vessels are poorly perfused compared to 
blood vessels in normal tissues (170). The main reasons for the poor 
vascularity are the constant activity of growth factors such as VEGF-A, 
PDGFs and FGFs and cytokines which are released by cancer cells and 
stromal cells in the tumour microenvironment causing proliferation of 
endothelial cells and thus leading to formation of new blood vessels. These 
continuous vascular activities in fact prevent vascular maturation (171). 
Furthermore, continuous vascular formation causes nascent blood vessels 
which are prone to rupture. Therefore, intravascular coagulation and fibrin 
deposition which can be seen in the tumour microenvironment is mainly 
due the rupturing of immature blood vessels and therefore anti-angiogenic 
therapies are used to prevent vascularisation and diminish carcinoma  
growth (172).  
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1.11.2.8 Pro-tumorigenic activities of Myofibroblasts 
It is generally believed that cancer cells cannot survive on their own unless 
they build a relationship with local and distant host cells, and indeed a 
morphological analysis of stromal cells clearly demonstrates the 
participation of host cells in the formation of primary tumours, as well as 
premetastatic and metastatic cancer cells (173). Myofibroblasts can be 
used in cancer prognosis and in ascertaining response to chemotherapies 
of malignant carcinomas. Immunohistochemical analysis of epithelial 
carcinomas revealed that, many functional proteins that are expressed in 
the tumour microenvironment are believed to be encoded by genes that are 
expressed by myofibroblasts (174). However, we need to consider that the 
tumour microenvironment is not only composed of cancer cells and 
myofibroblasts. Inflammatory cells are also attracted to the cancer 
microenvironment by excessive expression of pro-inflammatory cytokines 
produced by myofibroblasts. Although the response of myofibroblasts to 
cancer cells is emphasised towards cancer progression, however, 
transgenic mouse experiments suggest that resident tissue fibroblast cells 
initiate signals that down regulate cancer cell proliferation and tumour 
progression (175). 
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1.11.2.9 ECM of normal organs 
Stromal ECM is made up of a collection of different tissues including 
collagens, elastin, fibronectin, hyaluronic acid, proteoglycans and 
glycoproteins. The main function of ECM in healthy organ is to maintain 
tissue architecture. ECM is also capable of modifying the function of growth 
factors and cytokines (176). Furthermore, when growth factors and 
cytokines are released from the activated cells, the ECM provides them 
with biological latency and protects them from degradation. In the case of 
TGF-β for example, its activity and latency is governed by binding to a 
stromal proteins such as decorin or thrombospondin-1(177).  The activity of  
growth factors such as VEGF is controlled by binding to heparin or  
Proteogycans before triggering endothelial cell activation and proliferation. 
Breaking down of the ECM homeostasis is caused by imbalanced 
production and degradation of ECM which consequently leads to the 
disruption of tissue architectures. 
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1.11.2.10 ECM of solid tumour 
The collagen component of solid tumours is morphologically different to the 
collagen in normal connective tissue. The fibril portions of carcinoma 
tumours are multi-lobular and coarse, displaying a heterogeneous 
distribution of diameters. In normal connective tissue these collagen fibrils 
appear smooth and circular (178). Furthermore, the expression of collagen 
fibrils in solid tumours is considerably high compared to that in normal 
tissue. The synthesis of collagen in epithelial carcinomas is believed to be 
regulated by myofibroblasts (179). Cancer cells proliferate more rapidly 
than normal tissues and therefore require more energy, and these cells use 
collagen as a source of fuel for their growth and proliferation. Proline which 
is released as a result of collagen degradation by tumour cells is 
considered as a source of energy and also as a precursor for other amino 
acids (180). The activity of cross-linking enzymes such as Lysyloxidase is 
changed in solid tumours. The increased activity of these cross-linking 
collagen enzymes causes excessive collagen scaffolding stiffness which 
consequently increases the invasiveness of tumours (181).   
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1.11.2.11 Fluid balance in the tumour microenvironment 
Fluid balance is disturbed in the tumour microenvironment, and this is due 
to the immature vascular system of the tumour which is caused by 
excessive expression of angiogenic factors such as VEGF. The blood 
vessels become leaky and lose plasma protein in the tumour stroma that 
leads to a breakdown of osmotic pressure between the interstitium and the 
blood (182). The lymphatic system is also not functional at the standard 
level compared to normal tissue leading to a lack of drainage of excess 
interstitial water. The blood pressure in tumour stroma ranges between 7- 
31 mm Hg, thus leading to severe oedema. This in fact leads in to 
inefficient transport of water and other molecules in the tumour 
microenvironment. Furthermore, the transport of larger protein molecules is 
far less efficient compared to normal tissues. This is generally due to the 
excessive composition of the ECM which is orchestrated by myofibroblasts, 
carcinoma cells and TAM (183). 
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1.11.2.12 How injured epithelial cells respond to the microenvironment 
Epithelial cells are exposed to physical, chemical and pathological damage 
and can be repaired through the formation of granulation tissue, connective 
tissue produced by ECM deposition, fibroblast activation, endothelial 
proliferation and immune cell mobilization (184). Physiological repair 
mechanisms are carried out by the degradation of excessive ECM, and 
apoptosis of myofibroblasts. Inflammation is sustained when myofibroblasts 
remain active and continues with the production of ECM, MMPs, 
angiogenesis and immune cell influx. Therefore, the presence of continued 
inflammation, fibrotic lesions and excessive production of MMPs leads to 
the dissolution of the basement membrane which normally functions as a 
barrier between the epithelial tissue and stroma. Dissolution of this 
membrane disrupts the epithelial cell polarity and also the epithelial tissue 
becomes physically exposed to the inflamed microenvironment. It is 
unsurprising then that the risk of cancer is significantly increased in the 
target tissue (185). 
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1.12. AIMS OF THE PRESENT STUDY 
The objective of this thesis was to study the influence of cancer cell derived 
microvesicles on normal epithelial cell lines and primary fibroblast cells. 
 
In chapter III, the aim was to study the role Jurkat cell (T cell leukaemia 
cell line) derived microvesicles in generating phenotypic change of normal 
prostate epithelial cell lines (PNT2). 
 
In chapter IV, aimed to investigate causes and functional consequences of 
Epithelial Mesenchymal Transition in prostate epithelial cells induced by 
Jurkat cell derived MVs. 
 
In chapter V, the aim was to examine the influence of small lung cancer 
cell- (A549) derived microvesicles on primary fibroblast cell lines (MRC5), in 
the tumour microenvironment.
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
 
Annexin V Alexa Fluor 488                                                                                                                                            
Annexin V reagent 
BAPTA-AM 
BCA protein assay kit 
BSA (Bovine serum albumin) 
Calcium chloride 
DAPI-VECTASHIELD 
DMSO (Dimethyl sulfoxide) 
Ethanol 
Fura-2-AM 
FBS (Foetal Bovine Serum) 
Guava ViaCount reagent 
Guava Nexin reagent 
Halt Protease Cocktail 
HCl (Hydrochloric acid) 
Human FGF-1 ELISA kit 
Human MMP9 ELISA kit 
Human TGF-β1 ELISA kit 
Kanamycin 
Magnisium chloride 
Methanol 
NHS (Normal Human Serum) 
Paraformaldehyde 
PBS (Phosphate Buffer Saline) 
Penicillin / Streptomycin 
Potassium chloride 
Propidium iodide 
RPMI 
SB-431542 
Sodium azide 
Sodium chloride  
Sodium hydroxide 
Tris base 
Trichloroacetic acid 
Triton X-100 
Trypsin/EDTA solution 
Invitrogen 
R&D Systems  
Sigma-Aldrich 
Pierce Biosciences 
Sigma-Aldrich 
Sigma-Aldrich 
Vector Laboratories Inc, CA, USA 
Sigma-Aldrich                               
Fisher Scientific 
Sigma-Aldrich 
Fisher Scientific  
Guava Technologies, UK 
Guava Technologies, UK 
Pierce, Thermo-Scientific 
Fisher Scientific 
R&D Systems 
R&D Systems 
R&D Systems 
Sigma-Aldrich    
Sigma-Aldrich 
Fisher Scientific                                          
Sigma-Aldrich 
Agar Scientific 
Sigma-Aldrich 
Fisher Scientific 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Fisher Scientific 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Fisher Scientific  
Sigma-Aldrich 
Sigma-Aldrich 
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2.1.2 Technical devices  
AMT Digital camera                                
Cell culture flasks (75 cm2)    
Centrifuge 5804 R 
Centrifuge 5810 R  
Gel loading tips 
Guava EasyCyte flow cytometer 
Fluorescence microscope (1X81) 
FLUOstar Omega plate reader                                                                                                                                                                                                                                                                               
Incubator Heraeus CO2-Auto-Zero  
Microcentrifuge 5417R  
Microplate (12-well) 
Microplate (24-well) 
Microplate (96-well) 
pH-Meter 766 Calimatic     
Roto-Shake Genie  
Semi-dry transfer system 
Small volume tips 
Sorvall ultracentrifuge RC6 
Sorvall T-865 rotor 
F-20 micron rotor 
SE-12 rotor 
Advanced Microscopy Tech. 
Fisher Scientific 
Eppendorf 
Eppendorf 
Corning 
Guava Technologies, UK 
Olympus Corporation, Germany 
BMG Labtech, UK   
Thermo Electron Corporation 
Eppendorf 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Jenway 
Denley 
BioRad 
Sigma-Aldrich 
Thermo Electron Corporation 
Sorvall 
Sorvall 
Sorvall 
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2.1.3 Antibodies  
Anti-Annexin V AlexaFlour 488   
Anti-CD 25 FITC 
Anti- E-cadherin                                                                  
Mouse anti-IgG AlexaFluor 488 
Mouse anti-E-cadherin 
Mouse anti-FGF-1 
Anti- Smad3                                                                          
Anti- Smad3 (Phospho S423+ S425)                              
Anti- Vimentin                                                                     
Mouse anti-TGF-β1 
Mouse anti-IgG FITC  
Mouse anti Vimentin 
Rabit IgG anti- Human FITC                                               
 
Biosciences 
BioLegend 
Abcam 
Biosciences 
Abcam 
Abcam 
R&D Systems
Abcam
Abcam
R&D Systems 
AbD Serotec 
Abcam 
Abcam 
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2.1.4 Eukaryotic Cell lines 
Jurkat cells (Human T- cancer cells) were used in most experiments as the 
source of cancer cells derived vesicles (MVs). However, in some 
experiments, MVs were isolated from A549 cells (Non small lung cancer 
cells), MOLM 13 cells (human leukaemia cells) were used in some 
experiments. Primary monocytes were also obtained from healthy donors.  
Eukaryotic cell lines: MOLM 13 (Received as kind gift from Gareth Williams 
at UCL) 
A549 cells (Received as kind gift from Gareth Williams at UCL) 
Jurkat cells (ECACC; Ref No. 88042803) 
MRC5 cell (Received as kind gift from Gareth Williams at UCL) 
PNT2 (ECACC; Ref No. 86012803) 
PC3   (ECACC; Ref No; 92127018) 
 
2.1.5 Eukaryotic Cell Culture Media: Cell Growth Medium (GM) 
The RPMI 1640 supplemented growth medium was used to cultivate PNT2 
cells (immortalised prostate cells) and Jurkat cells. RPMI 1640 medium 
supplemented with 10% FBS (v/v) and 1% Penicillin / Streptomycin in 500 
ml volumes and stored at 4°C. 
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2.2 Experimental Solutions 
2.2.1 Mammalian cell freeze medium 
20% 
10%  
1%   
69%                                          
FBS (v/v)  
DMSO (v/v) 
Penicillin/Streptomycin (v/v) 
RPMI (v/v)
 
2.2.2 Lysis buffer- pH 7.4 
100 mM 
2 mM 
0.2%     
 
 
 
HEPES-KOH 
CaCl2 
Triton X-100 (v/v) 
Protease inhibitor (AEBSF) 
Millipore water 
Made up to 50 ml and stored as 1 ml aliquots at -20°C                      
 
2.2.3 (1.5 M) Resolving buffer- pH 8.8 
18.17 g          Tris base 
Dissolved in 100 ml deionised water and pH adjusted to 8.8  
 
2.2.4 Resolving gel solution (12%) 
2 ml  
1.25 ml 
0.050 ml  
1.66 ml  
0.025 ml  
0.0025 ml                                         
ddH2O 
1.5 M Tris-HCl, pH 8.8 
10% SDS (w/v) 
Acrylamide/Bis 30% (w/v) 
10% APS (w/v) 
TEMED
 
 
2.2.5Antibody dilution buffer (WB) 
3% 
100 ml                
Milk powder (w/v) 
PBS-T 
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2.2.6Permeabilisation Buffer (PB) 
0.5%                  Tween 20 (v/v)  
PBS 
 
2.2.7 Immunofluorescence antibody dilution buffers 
3.2.7.1Cell Dilution Medium 
10% 
1%                   
FBS 
NaN3 
PBS solution 
  
2.2.7.2 Primary and secondary antibody dilution buffer 
3% BSA (w/v) 
PBS 
 
2.2.8 Flow cytometry analysis buffer 
3% 
1%                     
BSA (w/v) 
NaN3 (w/v) 
PBS 
 
All components dissolved in 500 ml deionised water 
 
2.2.9 Annexin V binding buffer–pH 7.4 
10 mM 
140 mM 
2.5 mM                                        
HEPES/ NaOH 
NaCl 
CaCl2 
 
All components dissolved in 100 ml of deionised water 
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2.2 Methods 
2.2.1 Maintaining cell lines 
2.2.1.1 Non-adherent cell lines 
Non-adherent Jurkat cells was maintained in growth medium containing 
RPMI 1640 supplemented with 10% foetal bovine serum (FBS), 1% 
penicillin-streptomycin. In addition, cells were occasionally maintained for a 
week in growth medium supplemented with 1% kanamycin at 37°C in 5% 
CO2 atmospheric conditions. The cells were split, depending on confluency 
every 3 to 4 days by washing twice with serum-free RPMI 1640. The cells 
were transferred into 50 ml centrifuge tubes and spun at 160 g for 5 min. 
Resulting supernatant was discarded and cells were gently resuspended in 
the remaining medium. RPMI was added and cells were centrifuged as 
mentioned earlier. Resulting supernatant was discarded and cell pellets 
were resuspended in the appropriate volume of growth medium. Cells were 
then seeded in the desired dilution into new 75 cm2 culture flasks. Cells 
were only cultured in medium supplemented with kanamycin for a week to 
avoid development of resistance to the antibiotic.  
 
2.2.1.2 Adherent cell lines 
Adherent cells (PNT2) were also maintained at 37°C with 5% CO2, in RPMI 
growth medium. These cells were also split depending on confluency every 
3 to 4 days. Cells were washed twice by changing GM with serum-free 
RPMI and addition of 0.25% (v/v) trypsin/EDTA in RPMI. After 6 min 
incubation at 37°C with 5% CO2, the flask was tapped several times to 
Materials and methods 
 
74 
 
detach the cells and growth medium was added to inactivate the trypsin. 
The trypsin solution was removed by centrifugation at 200 g for 5 min 
followed by one wash in serum-free RPMI. Cell pellets were resuspended in 
the appropriate GM volume and seeded in the desired dilution into new 
culture flasks. Exponentially growing cells with viability of 95% or higher 
was used in every experiment. The number of cells and viability were 
determined before the start of every experiment using the flow cytometer 
(ViaCount assay, Guava Technologies). 
 
2.2.1.3 Freezing of eukaryotic cells 
To prepare frozen stocks for long term storage, non-adherent cells grown to 
almost 100% confluency were washed twice (160 g, 5 min) with serum-free 
RPMI and cell number determined using Guava viacount as mentioned in 
section 3.8.1.2. Cells were carefully resuspended in freeze mix, transferred 
into cryo-vials (Greiner) at 1x107 cells/ml in 1 ml volumes and immediately 
placed on ice. The cryo-vials were frozen at –80°C in special cryo boxes, 
which ensure a temperature decrease of 1°C per minute. For long-term 
storage the deep frozen cryo-vials were transferred to liquid nitrogen cell 
storage tanks. Adherent cells were also frozen by a similar procedure 
except that cells were first trypsinised to bri ng them into suspension, as 
described earlier. Suspended cells were washed by centrifugation at 200 g 
for 5 min. Cells were resuspended in the freeze mix and transferred into 
cryo-vials. 
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2.2.1.4 Thawing of cells 
To defrost cells, cryo-vials were removed from liquid nitrogen and 
immediately thawed in a waterbath at 37°C. After cleaning the lid with 70% 
ethanol, the content was transferred to a 15 ml centrifuge tube containing 9 
ml of fresh growth medium, prewarmed to 37°C and cells were sedimented 
by centrifugation at the appropriate speed (200g or 160 g, 5 min for 
mammalian cells). To remove DMSO, the medium was discarded and the 
pellet was resuspended in fresh growth medium. The cells were then 
placed into culture flasks of the same size as had been used prior to 
freezing, and incubated at 37°C with 5% CO2. 
 
 
2.3 Biochemical Methods 
2.3.1 Purification of MVs from medium 
Cells cultured supernatant containing 10% FBS (MVs free) was centrifuged 
once at 160g for 5 min to remove the cells. The supernatant was then 
centrifuged at 4,000 g for 1 hrs to remove cell debris. Supernatant was 
centrifuged at 25,000 g for 2 hrs to pellet MVs. Pelleted MVs were washed 
once by resuspending in sterile 0.1 µm filter PBS and centrifuged again at 
25,000 g for 2 hrs. The MV pellet was resuspended in sterile PBS and 
quantified, or analysed for PS exposure as described under section 3.9.1.  
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2.3.2 Annexin labelling of MVs 
Isolated MVs were resuspended in Annexin binding buffer and Guava 
Nexin-FITC was added or not (control) in a 100 μl final volume. Sample was 
then incubated at room temperature for 45 min with shaking and 
centrifuged at 25,000 g for 2 hrs to pellet MVs. Samples were analysed 
immediately as directed by the manufacturer using the flow cytometer 
(Guava EasyCyte, Guava Technologies).  
 
2.3.3 Measurement of intracellular calcium 
2.3.3.1 Omiga Plate reader 
PNT2 cells (1x106/ml) were washed twice with serum-free RPMI by 
centrifugation at 200 g for 5 min and incubated in 0.5 ml volumes with 2 mM 
Fura-2-AM at RT for 1 hrs in the dark with shaking. Labelled cells were 
washed a further three times with RPMI and resuspended in a physiological 
salt solution (PSS) containing 130 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 
10 mM HEPES in the presence or absence of 1 mM CaCl2 or 5 mM EGTA. 
Measurements were made before and after addition of Jurkate cells MVs 
after45 min with continual stirring, whilst monitoring fluorescence on a 
spectrofluorimeter at 505 nm upon excitation at 340 and emission at 380 n. 
Triton-X-100 (1%) was added after 150 seconds to measure the maximum 
fluorescence. Intracellular calcium was calculated using the equation: 
[Ca2+]i = Kd[(R-Rmin)/(Rmax-R)x(Sf2/Sb2)] where Kd (dissociation constant)  
for Fura-2-AM is 224 nM. R is the ratio of the emission intensities measured 
at 505 nm on excitation at 340 and 380 nm. R-min is the ratio of intensities 
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obtained at zero intracellular Ca2+ (before the addition of 1% Triton X-100 to 
cells resuspended in buffer containing 5 mM EGTA) and  
R-max is the ratio of emission intensities measured after lysing the cells 
with 1% Triton-X-100 thus allowing Fura-2 measurement in the maximum 
external calcium concentration of 1 mM.  
Sf2 is the emission intensities of free calcium measured at 380 nm [ratio of 
intensities measured after addition of 1% Triton-X-100 to cells resuspended 
in buffer containing with 5 mM EGTA (here, the calcium is free as it is 
bound to EGTA and not to Fura-2-AM)]. Sb2 is the emission intensities of 
bound calcium measured at 380 nm (ratio of maximum intensities 
measured after addition of 1% Triton X-100). All measurements were made 
at 37°C. 
 
2.3.3.2 Ion chromatography 
PNT 2 cells were transferred into marked 1.5 ml appendrof tubes. Pellet 
cells at 450 g for 5 minutes. Cells are resuspend it in 1 ml double distilled 
water. Tubes are dropped in liquid nitrogen to freeze and thaw sample on 
ice (thawing takes a few minutes). Vortex briefly and Repeat freeze-thaw 
cycle four more times. Samples were centrifuged at 450 g 10 minutes and 
the supernatants were transferred into new marked 1.5 ml appendrof tubes. 
Ion chromatograph is able to measure concentrations of major cations 
(lithium, sodium, ammonium, potassium, calcium) and anions, (fluoride, 
chloride, nitrate, nitrite, and sulphate). Ion chromatography is form of liquid 
chromatography that measures concentrations of ionic species by 
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separating them based on their interaction with a resin. Ionic species 
separate differently depending on species type and size. Sample solutions 
pass through a pressurized chromatographic column where ions are 
absorbed by column constituents. As an ion extraction liquid, known as 
eluent, runs through the column, the absorbed ions begin separating from 
the column. The retention time of different species determines the ionic 
concentrations in the sample. Small quantity of the sample (no less than 
100 um) are injected into the machine using a small sterile syringe. The 
syringe needle passes through a thick rubber disc (known as a septum) 
which reseals itself when the syringe is pulled 
 
2.3.4 Growth Inhibition Assays 
PNT2 cells were seeded into 12-well plates at 1x105 cells/well in triplicate. 
30 µg/ml jurkat cells derived MVs were added to each well (except controls) 
and plates were incubated at 37°C for 5 days. On the days indicated, PNT2 
cells were removed using typsin/EDTA and counted by ViaCount assay on 
a Guava EasyCyte flow cytometer.  
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2.3.5 Differentiation Assay 
PNT2 cells were determined following treatment with 30 µg/ ml of Jurkat 
cells MVs. To investigate EMT, PNT2 cells 1x104 cells/well were seeded 
into 24 well plates in triplicate. Cells were left untreated (control) or treated 
either with 30 µg Jurkat cells MVs and incubated at 37°C in a humidified 
atmosphere of 5% CO2 for five days. After 5 days the cells washed twice 
with ice cold double PBS and the attached cells were released with 
trypsin/EDTA. The trypsinised cells, in suspension were collected by 
centrifugation (200 g, 5 min) and immuno-labelled at 4°C for 1 h with the 
anti- E-cadherin antibody and anti- Vimentin antibody. 
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2.3.6 Determination of Protein Concentration 
The concentration of a protein solution was determined using the BCA 
Protein Assay Kit (Pierce, Thermo Scientific, UK). It uses a combination of 
the biuret reaction (reduction of Cu2+ ions to Cu+ ions by proteins in an 
alkaline medium) and the colorimetric detection of the Cu+ - cations by a 
bicinchoninic acid-containing colour reagent. Following the manufacturer’s 
instructions, 10 μl of protein samples were diluted in double distilled water 
(ddH2O; dilution 1:5) and added to 200 μ l working solution consisting of a 
mixture of kit reagent A and reagent B (ratio 50:1 respectively). In parallel a 
dilution series of a 0.5 μg/μl BSA stock solution in ddH2O were prepared 
and used as standard in later evaluation. Applied concentrations were 0, 
62.5, 125, 250, 500, 750, 1,000, 1,500 and 2, 000 μg/ml BSA in 500 μl 
ddH2O. Volumes equal to samples were added to 200 μl of a mixture of kit 
reagent A and B (ratio 50:1) in a 96 well plate followed by incubation at 
37°C for 30 min. After incubation at room temperature for 10 min to cool 
samples, Absorbance at 562 nm readings was taken on a FLUOstar 
Omega microplate reader. Protein concentrations of the unknown samples 
were determined by interpolation on a standard curve multiplied by a 
dilution of factor of 5. 
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2.3.7 Preparation of cell lysates 
PNT2 cells (1x106) grown in culture flasks, after removing the medium, cells 
were trpsininsed and sedimented by centrifugation (200 g, 5 min at 15°C). 
The pellet was washed once by careful resuspension in RPMI followed by 
centrifugation. After that, cells were counted using a haemocytometer and 
lysis was performed to give a protein concentration. If defined amounts of 
protein were required, the pellet was subjected to detergent based lysis 
followed by determination of total protein concentration using procedure for 
the BCA kit according to the procedure described under section 3.9.11.  
Briefly, cell lysis was performed by resuspension of the pellet in 0.2% Triton 
X-100 (w/v) containing protease inhibitor cocktail. To solubilise membrane 
proteins, samples were repeatedly pipetted and insoluble materials were 
sedimented by centrifugation (10,000 rpm, 5 min at 4°C, A-4-62 swing-out 
rotor, using 5810R centrifuge, Eppendorf).  The total protein concentration 
was determined of the resultant supernatant and then subjected to SDS-
PAGE analysis. 
 
2.3.8 Sample preparation for SDS-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
SDS sample buffer (4X) was added to samples in a ratio of 1:4 followed by 
incubation at 95°C for 4 min. Before loading the samples onto the gel a 
centrifugation step was performed (2,000 g, 1min) to collect all liquid at the 
bottom of the reaction microtube and loaded into the gel wells.  
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2.3.9 SDS-PAGE Protein Molecular Weight Standards 
As a protein molecular weight standard, prestained Protein-Marker I 
(BioRad) was used. Prestained markers, ranging from 2 to 212 kD or 10 to 
250 kD were used when analysing gels by Western blot using the ECL 
detection system. Markers were applied by loading 10 µl into wells. 
 
2.3.10 SDS-Polyacrylamide Gel Electrophoresis 
To separate proteins, which were denatured by sodium dodecyl sulphate 
(SDS) according to their molecular masses, SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed as described (Laemmli, 1970) 
using the Mini PROTEAN III Electrophoresis System (Bio-Rad). Gels with 
dimensions of 102 x 73 mm and a thickness of 0.75 mm were cast between 
two glass plates by pouring freshly prepared 12% separating gel solution 
containing acrylamide/bisacrylamide into the gel cassette fixed in a casting 
frame. Unpolymerized separating gel solution was overlaid with H2O-
saturated butanol to achieve an even surface. After polymerization, H2O-
saturated butanol was poured off, washed twice with deionised water, and 
the excess water was blotted using a filter paper (Whatman 3 MM, 
Whatman AG). Then unpolymerized stacking gel was poured into the gel 
cassette and a plastic comb was inserted from the top, to form the loading 
wells in the stacking gel. After polymerization, the gels were used 
immediately. To perform electrophoresis, the gel was placed into the 
electrode assembly device inside a clamping frame in the tank of the Mini 
PROTEAN III system.  
Materials and methods 
 
83 
 
Electrophoresis running buffer was added to the inner and outer chambers 
of the tank and the plastic comb was carefully removed. Wells were washed 
with the running buffer to remove any free unpolymerized 
acrylamide/bisacrylamide. Samples were loaded into the wells of the 
stacking gel using extra long loading pipette tips. Electrophoretic separation 
was performed at 150 V (constant voltage) until the bromophenol blue front 
of the SDS sample buffer reached the end of the resolving gel. Gels were 
either stained with Coomassie Brilliant Blue or transferred onto 
nitrocellulose membrane for Western blotting analysis. 
 
2.3.11 Flow cytometry 
The Guava flow cytometer allows complex biological studies such as cell 
counting and viability testing, cytokine detection, cell activation marker 
analysis and other complex molecular analyses to be performed 
simultaneously. This saves time, but also generates accurate results, which 
comes much closer to mimicking the complex biological responses within 
the body. The Guava flow cytometer can be used to perform ten different 
assays; however, for these studies only three assays were implemented. 
These were the ViaCount assay (for counting cells and determining 
viability), ExpressPlus assay (for cell activation marker analysis, cytokine 
expression, microvesicle analysis and studies on protein-protein interaction),  
Nexin assay (for reporting apoptosis) and cell cycle analysis. 
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2.3.12 Cell counting and viability assessment 
Cell number and viability were determined using the ViaCount assay, which 
distinguishes between viable and non-viable cells based on the differential 
permeabilities of two DNA-binding dyes in the Guava ViaCount reagent. 
The nuclear dye only stains nucleated cells, while the viability dye brightly 
stains dying or dead cells. This proprietary combination of dyes enables the 
Guava ViaCount assay to distinguish viable, apoptotic and dead cells. Cell 
debris is excluded from results based on negative staining with the nuclear 
dye. 
 
2.3.13 Cell labelling 
PNT2 cells were washed three times with serum-free RPMI prior to 
experiments. Cells were labelled with MMP 9 and AlexaFluor 488, at RT for 
1 h with shaking at 4oC. MMP9 AlexaFluor 488 was diluted in a binding 
buffer provided with the kit and used at 1 µg/106 cells, according to the 
manufacturer’s instructions. Cells were washed three times with serum-free 
RPMI and then diluted in 200 µl of flow cytometer dilution buffer prior to 
examination by guava flow cytometer. 
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2.3.14 Immunofluorescence staining for EMT markers  
In order to determine the expression of cell activation markers as well as 
surface and intracellular cytokines by specific antibody staining, cells were 
processed according to the following protocol and analysed using flow 
cytometry. Cells were harvested, washed by centrifugation at 200 g for 5 
min and total cell number and viability (usually >95%) was determined 
using ViaCount reagent (refer to 3.10.1). Cells were usually stained in 
eppendorf tubes and later transferred into a 96-well microtiter plate for 
analysis on the flow cytometer. However, they can also be stained in 
polystyrene round-bottom, 12 x 75 mm Falcon tubes.  Cell surface 
expression of E-cadherin molecules were analysed by flow cytometry 
(EasyCyte, Guava Technologies, UK).  PNT2 cells (1 x 106) were washed 
twice (200 g, 5 min each) with PBS and resuspended in ice cold PBS 
containing 10% FBS and 1% NaN3. Cells were incubated in the dark with 
primary antibodies (2 µg/million cells, Abcam) against tested molecules at 
4°C for 1 hrs with shaking. After three washes (400 g, 5 min), cells were 
stained with the isotype-matched controls (anti-mouse or anti-rabbit IgG-
FITC, Abcam) diluted 1: 200 in PBS with 3% BSA and incubated with 
shaking, in the dark, at 4°C for 1 hrs. Cells were again washed three times 
with cold PBS, resuspended in 200 µl of PBS containing 3% BSA, 1% NaN3 
and analysed immediately using flow cytometry and the ExpressPlus assay 
program. For staining of intracellular expression, PNT2 cells (1x106/ 
reaction) in triplicate were resuspended in PB (0.5% Tween 20 in PBS) at 
room temperature for 20 min.  
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Cells were permeabilised by washing three times with PB and incubated 
with 2 µg of primary antibody (anti-Vimentin antibody) at 4°C for 1 hrs in 
PBS with 10% FBS/ 1% NaN3. Cells were washed three times and 
incubated with IgG-FITC-labelled secondary antibodies (4°C, 1 hrs), and 
again washed three times with ice cold PBS. Samples were resuspended in 
200 µl each of PBS containing 3% BSA, 1% NaN3 and analysed 
immediately by flow cytometry. 
 
2.3.15 Fluorescence microscopy 
For fluorescent microscopy analysis, PNT2 cells, cultured on coverslips 
were fixed with 4% paraformaldehyde at 37oC for 15 min. Plates were 
gently washed three times with ice cold PBS and coverslips were mounted 
on microscope slides with DAPI-VECTASHIELD medium. Images were 
collected using fluorescence microscope (1X81 motorized inverted 
fluorescence microscope, Olympus Corporation). 
 
2.3.16 Quantitation of proteases by ELISA 
MVs were isolated from PNT2 and transform PNT2 cells and the 
concentration of MMP 9 measured in MMP9 ELISA kits (Abcam) according 
to the manufacturer’s instructions. In some experiments, PNT2 and 
transform PNT2 cells (1x104/ well), in duplicate lysed before measuring the 
proteases level in target cells. 
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2.4 Statistical Analysis 
Statistical analysis for all data presented was performed by using 
GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, 
USA). Statistical correlations between data values were also determined 
using GraphPad Prism software. Differences giving a value of P < 0.05 with 
confidence interval of 95% were considered statistically significant.  
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3. Microvesicles from a T lymphocytic leukaemia cell 
lines (Jurkat) and induction of Epithelial 
Mesenchymal Transition of normal prostate 
epithelial cell lines 
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3.1 Introduction 
The Jurkat cell line was established in 1970 from the peripheral blood ofa14 
year old boy with T lymphocytic leukaemia. This immortalized blood cancer 
cell line is used primarily to determine the susceptibility of cancer cells to 
chemotherapy and radiotherapy. The precedent for my line o f investigation 
into the role of T cell leukaemia MVs is two-fold based firstly on evidence 
from the literature that mammary epithelial tumour cells are stimulated by 
activated CD8 T cells to undergo EMT, acquire resistance against 
chemotherapeutic agents and increase their tumorigenic capability. 
Secondly, from previous work showing Jurkat MVs to express high levels of 
TGF-β1 in a form that can be functionally activated (Ansa-Addo, 2010) and 
because of the described role of TGF-β1 in EMT. 
The objective of this study was to have an insight into the role Jurkat cell-
derived MVs have in the phenotypic change of normal prostate epithelial 
cell lines. EMT is a fundamental physiological process by which epithelial 
cells lose their epithelial characteristic (limited intercellular space, free 
apical surface, vascular and mitotic capability) and acquire mesenchymal 
characteristics (spindle shaped, end-to-end polarity). There are three types 
of EMT, physiologic EMT (Type I), Fibrotic EMT (Type II), and cancerous 
EMT (Type III). Type I EMT is the best characterised during organogenesis, 
Type II EMT is activated during wound healing and type III is a pathologic 
process that is functional during cancer invasion and metastasis.  
Microvesicles comprise a heterogeneous population of particles (0.1 to 1µm 
in diameter) derived from normal and cancer cells under physiological and 
stressed conditions, and act as communicative vectors between cells. 
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3.2 Results 
3.2.1 MV enumeration, characterisation and detection of exposed 
phosphatidylserine 
Jurkat cells MVs were used in this study to determine their biological effects 
on normal prostate epithelial cell lines. MVs were isolated according to the 
method described in the Materials and Methods, from Jurkat cell culture 
medium containing10% MV-free FBS without antibiotics. Calcium-free PBS 
was used during the washing steps and to dilute the MVs in the last stage 
of MVs isolation. PBS was also fi ltered through a 0.1 µm pore size filter to 
remove particles that otherwise might interfere with MV analysis using the 
EasyCyte Guava Flow Cytometry (Millipore) and Guava express plus 
software. The analysis of MVs using this program is quite challenging and 
is mainly due to the lower sensitivity of this technique for MV analysis. 
However, to minimise the miscalculation of MV numbers with background 
noise using the Guava EasyCyte technology, I decided to place less of an 
emphasis on MV number. Rather, protein quantification of MVs was utilised 
using the FLUOstar Omega plate reader (Bio-Rad). Therefore, PNT2 cells 
were treated according to the protein content of blood cancer MVs rather 
than their number. 
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3.2.2 MV quantitation and characterization 
This study is generally performed in every microvesicle laboratory, firstly to 
confirm the MV purification method has been performed correctly, secondly 
to have an approximate estimation of MV numbers harvested from the 
parent cells and thirdly, to look at the size and granularity of MVs from the 
FSC and SSC respectively.  
 
  
 
Figure 4.1 The direct analytical method of MVs performed using the Guava Easy Cyte. 
This scatter plot shows the number of MVs isolated from 70 ml conditioned (Jurkat) 
cell culture medium. The Guava Easy Cyte is a versatile technique for counting and 
characterizing MVs compared to the sophisticated electron microscope simply because 
it does not disturb the physiological property of MVs and unlike Nanosight Tracking 
Analysis enable other parameters such as the granularity of the sample to be 
determined and determination using fluorescence. The Guava Express software is used 
to gate the MVs and afterwards, analyze the relative proportion of MVs expressing 
phosphatidyleserine on their outer surface. Thus MVs were characterized by their size 
and granularity which was assessed from the logarithmic amplification of forward 
scatter (FSC) and side scatter (SSC) signals. 
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Essentially, this Guava EasyCyte technology uses a single screen 
dashboard of flow cytometer where simplified ease of use and the use of 
single colour further simplifies the data acquisition. However, this 
instrument has a throwback. As the particles below 0.2 µm cannot be 
detected by this machine, therefore MVs with range of 0.1 to 0.2 µm cannot 
be discriminated from the instrument noise.  Furthermore, another major 
element that is absent from this technique which in fact undermines the 
accuracy of the assay is the ability to compensate for signal crossover 
when both fluorescent channels are used. This crossover signal effect that 
compromises the assay’s accuracy is partially dependent on the 
fluorophores used and laser chosen for the system. 
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Figure 3.2 MVs labelled with Annexin V for the expression of 
phosphatidylserine that has translocated to the outer leaflet of MVs. (A) 
shows the flow cytometric analysis of MVs that labelled with Annexin V. MVs 
isolated from Jurkat cells were labelled with Annexin V according to 
manufacturer’s instructions. Adding 5 µl of fluorochrome conjugated Annexin V 
was added to 100 µl of the MVs suspension and incubated at R.T for 30 min 
whilst protected from light.  After incubation the sample was analyzed twice. 
After the first wash, 60 % of the MV population turned up positive with Annexin 
V and after the second wash by centrifugation at 25.000g and resuspension in 
200 µl of 0.1 µm sterile filtered PBS, the percentage of Annexin V-positive MVs 
went up to 66% presumably due to the reduction of Annexin V-negative MVs 
after high speed centrifugation.  
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At this point it was important to establish the nature of those 
vesicles/particles which were counted as MVs by the flow cytometer but 
stained negative for Annexin V.  Figure 4.2 above illustrates the purification 
of MVs after staining with Annexin V. A Student’s t-test between the two 
steps of centrifugation did not show a high significance. Overall my 
emphasis on these different ways of analysing samples was to make sure I 
was working with a pure population of biologically active MVs. 
 
3.2.3 Flow cytometry shows loss of E-cadherin expression in PNT2 
cells treated with T cell leukaemia-derived MVs 
Prostate epithelial cells (5x 104/well) were seeded into 24 well plates in 
triplicate and grown in medium containing 10% FBS and treated with 30 
µg/ml of Jurkat MVs. Cells were incubated for 5 days in (37oC and 5% CO2).  
Cells were monitored every 24 hrs using a phase contrast microscope and 
pictures were taken from both panels of control, untreated PNT2 cells and 
PNT2 cells treated with blood cancer MVs. On day 5, cells were washed 
and detatched by trypsin/EDTA, fixed with 4% PFA for 15 min then labelled 
with anti-E-cadherin antibody.  The expression of E-cadherin was 
measured in both control and MV-treated cells using the Guava EasyCyte. 
E-cadherin protein is a cell junctional protein which is expressed on the 
cytoplasmic membrane of all epithelial cells. E-cadherin has long been 
known as an epithelial cell marker and its expression is significantly 
reduced in carcinomas of epithelial origin.  
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Figure 3.3 Decreased expression of  E-Cadherinon  PNT2 cells treated with Jurkat 
MVs. This figure shows the effects of Jurkat cell MVs on E-cadherin expression of PNT2 
cells. (A) The expression of E-cadherin in PNT2 cells under basal condition. (B) E-cadherin 
expression in PNT2 cells treated with 30 µg/ml Jurkat MVs. (C) Combination of (A) and (B). 
(D) Shows the percentage reduction of E-cadherin in PNT2 cells treated with Blood cancer 
cells derived MVs. ***P<0.001. 
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C D *** 
Control, untreated PNT2  PNT2 + Jurkat MVs 
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The adhesion molecule E-cadherin is generally recognised as an epithelial 
marker. Loss of this junctional protein causes epithelial cells to reorganise 
their cytoskeletal proteins and consequently gain a mesenchymal 
phenotype. Loss of E-cadherin further causes epithelial cells to grow apart 
and no longer establish an epithelial sheet, this being an important hallmark 
of epithelial cell lines. Reduction of E-cadherin protein expression in PNT2 
cells from 69% in the control panel to 23% in Jurkat MV-treated cells 
caused loss of cell-cell contact. This reduction in almost all cases changes 
the phenotypic characteristic of epithelial cells, such that loss of adhesion 
molecules in PNT2 cells can be accompanied by a gain of mesenchymal 
characteristics. In order to determine whether PNT2 cells had acquired 
mesenchymal characteristics, PNT2 cells were observed under the 
microscope for morphological changes and the cells were further stained 
with anti-E-cadherin antibody for fluorescent microscopic analysis. 
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3.2.4 Fluorescent microscopic analysis shows loss of E-cadherin 
expression in PNT2 cells treated with T cell leukaemia-derived MVs 
To determine whether loss of E-cadherin protein expression in PNT2 cells 
causes EMT, I grew the PNT2 cells on coverslips in 24-well plates. The 
cells (5x105/well) were seeded for 14 hours in medium supplemented with 
10% MV-free FBS. Cells were then washed twice with serum-free RPMI, 
fresh complete growth medium being added into each well and 30 µg Jurkat 
MVs (protein quantification method 2.3.6) added into each well except 
control group. The experiment was incubated for 5 days at 37oC, 5% 
CO2.The cells were then washed three times with ice cold PBS and fixed 
with 4% PFA and labelled with monoclonal anti-E-cadherin antibody. In 
order to stain the nucleus, the coverslips were removed and stained with 
DAPI- VECTASHIELD medium. 
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Figure 3.4 PNT2 cells treated with T cell leukaemia-derived MVs show marked 
loss of E-cadherin expression as determined by fluorescent microscopy. (A), 
expression level of E-cadherin in control, untreated PNT2 cells. (B), nuclear 
staining using DAPI-Vectashield. (C), combination of (A) and (B). (D), expression 
level of E-cadherin on PNT2 cells treated with 30 µg/ml Jurkat MV for 5 days. (E), 
shows nuclear staining and (F), is combined (D) and (E). Fig.3.4 illustrates the 
level of E-cadherin molecules and also the anatomical location of this protein on 
control PNT2 cells. Comparing (A) with (D) treatment groups, E-cadherin 
expression significantly decreased in MV-treated cells. Scale bar = 50µm. 
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3.2.5 Flow cytometric analysis of Vimentin expression following 
treatment of PNT2 cells with Jurkat MVs 
Vimentin is as an intermediate filament protein which is an important part of  
the cytoskeleton present in almost all mammalian cells. It is mainly in the 
cytoplasm and partially in the nucleus of cells, and is recognised as a 
mesenchymal marker. The experiment for Vimentin expression in PNT2 
cells was setup the same way as for E-cadherin. The only difference is that 
as Vimentin is a cytoskeletal protein expressed mainly in the cytoplasm, 
after fixing cells with 4% PFA, cells were permeabilized with Triton X-100 
(0.1%) and then labelled with monoclonal anti-Vimentin antibody.  
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Figure 3.5 Expression of Vimentin is significantly up regulated on PNT2 cells 
upon treatment with T cell leukaemia (Jurkat) MVs. (A), Histogram showing 
Vimentin expression on untreated control PNT2 cells by flow cytometry. (B), 
Histogram showing Vimentin expression on PNT2 cells treated with Jurkat MVs 
(30 µg/ml). (C), Bar chart showing expression level of Vimentin in (A) and (B). 
(D), Summary of expression level in PNT2 cells of Vimentin and E-cadherein 
upon addition of Jurkat MVs, together with controls panels.***P<0.001.  
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The results in Fig.3.5 indicate that normal prostate epithelial cell lines 
cultured with MVs derived from T lymphocyte cancer cells acquire 
phenotypic changes. The PNT2 cells appeared mesenchymal-like, and at 
the molecular level cells in the experimental group expressed high levels of 
the mesenchymal marker, Vimentin (C) and significantly low levels of E-
cadherin (D). This data indicates that MVs derived from leukaemic T 
lymphocytes induce EMT in normal prostate epithelial cell lines. However, it 
is still not clear that the phenotypic changes taking place are necessarily 
normal developmental EMT, as opposed to inflammatory or tumorigenic 
EMT. If we consider the background of the MVs used (derived from a T cell 
leukaemia) it could probably be either of them.   
 
3.2.6 Fluorescent microscopic analysis shows significantly more 
Vimentin to be expressed in PNT2 cells treated with T cell leukaemia-
derived MVs 
Following measurement of the cytoskeletal protein, Vimentin in PNT2 cells 
by flow cytometry the cellular location and extent of expression of this 
intermediate filament protein was assessed using immunofluorescent 
labelling. The method was as described (2.2.6), except that 
permeabilization of the target cells was carried out using Triton X-100 
(0.1%). Vimentin is a mesenchymal marker being expressed only in 
mesenchymal cells, and it is the most important cytoskeletal protein 
participating in tumour progression and metastasis, malignant cancer cells 
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expressing higher levels than benign tumour cells. Vimentin is closely 
associated with cell motility both in normal and cancer cells . 
 
 
 
 
 
 
 
 
  
   A B C 
D E F 
Figure 3.6 Expression of the cytoplasmic intermediate filament protein, 
Vimentin, is significantly increased in normal prostate epithelial cells treated 
with blood cancer cell-derived MVs. (A), Vimentin expression on untreated, 
control PNT2 cells as assessed by fluorescent microscopy. (B), shows DAPI-
Vectashield staining of control PNT2 cell nuclei. (C), is the combined image of 
(A) and (B). (D), shows increased fluorescence with anti-Vimentin MAb on 
PNT2 cells treated with 30 µg/ml Jurkat-derived MVs. (E) indicates the nuclei of 
the cells in (D) and (F) represents the combined image of (D) and (E).Scale bar = 
50µm.         
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Fig.3.6 shows the amount of expression of the cytoskeletal protein, 
Vimentin, in PNT2 untreated, control cells and in the presence of blood 
cancer cell derived-MVs. The expression of Vimentin is significantly lower in 
normal epithelial cells (red arrows in Fig.4.6.A&C) compared with the 
amount of Vimentin expressed in PNT2 cells treated with Jurkat cell-derived 
MVs (Fig.4.6.D&F). Only epithelial cells undergoing EMT in cancer or 
fibrosis, transforming into mesenchymal-like cells, express the intermediate 
filament protein, Vimentin. These results demonstrate that cancer cell-
derived MVs actively participate in the EMT process. MVs, as intercellular 
vectors carrying cytokines, receptor proteins and miRNAs are able to 
induce changes in recipient cells. Indeed previous findings at CMIRC 
showed MVs able to induce terminal differentiation of monocytic cells 
through the delivery of TGF-β, tethered to the surface of the MVs (186). 
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4.2.7 Anti-TGF-β1pre-exposure of Jurkat MVs reduces the down 
regulation of expression of E-cadherin upon addition to PNT2 cells  
TGF-β1 is an important inducer of EMT especially in the inflammatory and 
cancer microenvironment. In an attempt to see whether TFG-β1 on Jurkat 
cells can participate in the process of EMT of prostate epithelial cells, MVs 
were treated with anti-TGF-β1 antibody (15µg/ml),incubated for 2 hrs and 
centrifuged at 25,000 g for 2hrs to remove any non-specifically bound 
antibody. The MVs were resuspended in MV-free, sterile, PBS and the 
experiment was set up as before (3.2) in 24-well plates, the PNT2 cells 
being exposed to T cell leukaemia (Jurkat) MVs for 5 days. There now was 
a reduced % of cells expressing E-cadherin upon treating with MVs pre-
incubated with MAb, anti-TGF-β1 (Fig. 4.7A)? The reduction of expression 
with MVs (66%) was reduced to only a 40% reduction when TGF-β was 
blocked with antibody (Fig. 4.7, B and C). 
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Figure 3.7 Flow cytometric analysis of reduction in E-cadherin expression following 
treatment of PNT2 cells with Jurkat MVs pr-incubated with anti-TGF-β1 (A) shows the 
histogram from the flow cytometry analysis of E-cadherin expression on PNT2 cells, 5 
days following addition of T leukaemia cell-derived MVs where TGF-β1 had been pr-
blocked with MAb against TGF-β1. In (B) the level of expression of E-cadherin is expressed 
as the % of positive cells. (C) Shows the percentage reduction of E-cadherin in the 
presence or not of anti-TGFβ1. ***p<0.001; **p<0.01; *p=0.05. 
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That EMT was still occurring, even in the absence of at least some of the 
MV-derived TGF-β1 was confirmed by microscopy analysis of the PNT2 
cells following addition of Jurkat MVs in terms of maintenance of 
mesenchymal morphology (Fig. 3.8) and continued decreased expression 
of E-cadherin (albeit not as reduced, as determined quantitatively, Fig. 3.7). 
It is through the extracellular domain of E-cadherin that neighbouring 
epithelial cells adhere together to form junctional complexes and when 
PNT2 cells are cultured with MVs, and by microscopy analysis it is clear 
that this junctional complex is degraded. However the morphology of the 
PNT2 cells is not completely disturbed. At the microscopic level Jurkat MVs 
in the presence of anti-TGFβ1 also showed reduced expression of E-
cadherin on PNT2 but it is not possible to make quantitative comparisons 
as to the degree of reduction compared to that achieved by MVs alone 
(Fig.3.4). 
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Figure 3.8 PNT2 prostate cells express E-cadherin on the cell surface as 
shown by fluorescent microscopy but this is reduced upon addition of Jurkat 
cell-derived MVs pre-incubated with MAb, anti-TGF-β1. (A), E-cadherin 
expression at the cellular junctions of untreated, control PNT2 cells as 
assessed by fluorescent microscopy. (B), shows DAPI-Vectashield staining of 
control PNT2 cell nuclei. (C), is the combined image of (A) and (B). (D), shows 
increased fluorescence with anti-E-cadherin MAb on PNT2 cells treated with 
30 µg/ml Jurkat-derived MVs. (E) indicates the nuclei of the cells in (D) and (F) 
represents the combined image of (D) and (E). Scale bar = 50µm.     
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3.2.8 Jurkat MVs pre-exposed to anti-TGF-β reduce the up regulation 
of expression of Vimentin upon addition to PNT2 cells  
The role of TGF-β1 in the expression of the intermediate filament Vimentin 
is demonstrated during wound healing as well as cancer progression and 
metastasis. During inflammation, cytokines released by various immune 
cells participate in fibrotic EMT. In the case of carcinomas of epithelial 
origin, the EMT signalling pathway is used by cancer cells to invade the 
local microenvironment and to metastasize to distant locations to establish 
secondary tumours. There is always a strong positive correlation between 
the level of Vimentin expression by cancer cells and prognosis; more 
aggressive types of cancer cells expressing higher levels of Vimentin than 
benign epithelial tumours. In order to examine the possible role of TGF-β1 
present on MVs in causing EMT, MVs were treated with monoclonal anti -
TGF-β1 before adding them as an activator of EMT signalling to prostate 
epithelial cells. 
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Figure 3.9 The increased expression of Vimentin on PNT2 cells upon exposure to Jurkat 
MVs was decreased if pre-exposed to anti-TGFβ MAb (A), expression levels of Vimentin 
in PNT2 cells treated with Jurkat cell derived-MVs and with Jurkat MVs pre-treated with 
anti-TGFβ1 MAb. (B), bar charts showing expression level of Vimentin in control, 
untreated PNT2 cells and in PNT2 cells treated with Jurkat MVs pre-exposed to MAb 
against TGF-β1. The second graph compares the % increase between MV alone treatment 
and MV pre-exposed to anti-TGFβ1. (C), Expression level of Vimentin on PNT2 cells 
treated with leukaemia cell derived-MV pre-treated with MAb against TGF-β1. (D), 
Nuclear staining of using DAPI-Vectashield. (E), Combination of (C) and (D). Scale bar is= 
50µm ***p<0.001; **p<0.01; *p=0.05. 
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Having shown Jurkat cell derived-MVs to induce EMT in normal PNT2 
epithelial cells, in the following experiments I pre-incubated MVs with MAb 
against TGF-β1 in order to attempt to neutralize any effect  of TGF-β on 
inducing EMT. I found that the % expression of Vimentin was reduced from 
a 150% increase with MVs compared to untreated control to 80% when 
using MVs pre-incubated with anti-TGFβ1 implying that despite blocking 
microvesicular TGF-β1 EMT is still being maintained but at lower level and 
that TGF-β1 may be playing a partial role. Vimentin expression was still 
clearly detectable in the PNT2 cells treated with blood cancer cell derived-
MV using fluorescence microscopy analysis (white arrows (Fig.3.9 C and 
E). According to these results I propose that MVs derived from leukaemia 
blood cancer cells induce EMT in normal prostate epithelial cells and that 
this may partially be due to the effect of TGF-β that is carried by these MVs. 
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3.3 Summary 
EMT is a physiological process in which epithelial cells are disseminated 
from the surrounding epithelial tissue and acquire mesenchymal-like 
properties. There are three types of EMT identified so far that depend on 
the type of inducer namely whether it is physiological, fibrotic or cancerous. 
Cells undergoing EMT are capable of migrating from the epithelial layer to 
distant sites and the transformation of epithelial cells to mesenchymal-like 
cells can be temporary or permanent depending on the inducers. There is 
much evidence in the literature suggesting that immune cells such as CD8 
T positive cells can produce EMT mediators. In this chapter I have tried to 
ascertain whether MVs derived from T lymphocyte cancer cells (Jurkat cells)  
carry EMT mediators from the parent cells that have the potential to induce 
EMT in normal prostate epithelial cells. PNT2 cells were therefore grown in 
the presence of Jurkat cell-derived MVs for up to 5 days. The influence of 
blood cancer cell derived MVs was determined by the measurement of the 
epithelial marker (E-cadherin) and mesenchymal marker (Vimentin) on 
control, untreated PNT2 cells and MV-treated PNT2 cells. EMT was 
confirmed by:   
1. Significant reduction in the expression of epithelial marker (E-cadherin);  
2. Significant increase in the production of mesenchymal marker (Vimentin). 
3. Morphological changes that occur during EMT in epithelial cells, gaining 
mesenchymal characteristics.    
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In order to understand the mechanism of the observed EMT, I investigated 
the TFG-β signalling to see if this cytokine carried by these MVs could 
cause EMT in PNT2 cells. It is one of the most important cytokines 
produced by T cells and is present in MVs. Furthermore, TGF-β is also 
believed to be one of the causes of EMT in the cases of fibrosis and 
carcinoma of epithelial origin. According to these results, by blocking TGF-β 
signalling the MVs still causes reduction of epithelial marker (E-cadherin) 
and increase expression of mesenchymal marker (Vimentin) but to a lesser 
extent than with MVs alone. It is important to consider that the TGF-β may 
not have been activated fully on delivery of the Jurkat MVs to PNT2 cells as 
it is in a latent complex which needs either contact with integrins or 
activation by plasmin to release the active homodimer. If this process was 
limited the blocking anti-TGF-β may not have been fully able to block any 
TGF-β-mediated effects on EMT. The process of TGF-β activation on MVs 
is part of ongoing work at Cellular & Molecular Immunology Research 
Centre. 
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3.4. Schematic diagram of immune cell derived MVs induce EMT in 
PNT2 cells 
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4. Causes and functional consequences of EMT in 
normal epithelial cells induced by leukaemia cell 
derived-MVs
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4.1 Introduction 
Epithelial Mesenchymal Transition is a highly specialized physiological 
process that is defined by loss of epithelial characteristics and acquisition of 
a mesenchymal phenotype and is regulated by various transcription factors 
including members of the Zeb, Snail and Twist families. The functional 
consequences of EMT generally depend on the EMT regulators and this 
phenotypic process is not always permanent. During morphogenesis 
primary epithelial cells undergo EMT to induce morphogenesis such as 
neural crest formation and heart valve formation.  Therefore, the functional 
consequences of this type of EMT are purely physiological taking place for 
developmental purposes. The EMT involved during the process of wound 
healing is termed fibrotic EMT. In this process keratinocyte cells at the edge 
of the wound transform to mesenchymal-like cells. This type of EMT is also 
a physiological function of cells in the epithelial tissue during cell injury and 
inflammation. In the case of epithelial cell injury and inflammation, fibrotic 
EMT is activated to close the gap and prevent pathogens getting deeper 
into tissues and organs in order to prevent further damage. The purpose of 
this type of EMT is therefore protective. The EMT taking place during 
cancer progression is called cancerous EMT and is a pathological process 
which takes place in carcinoma of epithelial origin. Cancer cells are 
believed to highjack this physiological process, firstly, to disseminate from 
the primary tumour and invade tumour microenvironment and secondly, to 
get into blood circulation and the lymphatic system in order to establish a 
secondary tumour in the distant organ.   
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In this study, I was trying to demonstrate the type of EMT induced by 
cancer cell-derived MVs on normal prostate epithelial cells that was 
performed in the first chapter of this thesis. I therefore performed a range of 
assays to assess the functional consequences of this particular MV-induced 
cancerous EMT. 
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4.2 Results 
4.2.1 Cytosolic calcium measurement 
Calcium is believed to play an important role as a secondary messenger in 
multiple intracellular pathways. The role of calcium signalling in the 
induction of EMT in breast cancer cells has been well documented over the 
past years. Here in the second chapter of this thesis, I have examined 
whether cancer cell-derived MVs induce EMT associated with a remodelling 
of Ca2+ in the normal prostate epithelial cell lines. To assess the cause of 
EMT in PNT2 cells treated with Jurkat cell-derived MVs, epithelial cells 
were exposed to MVs pre-treated by Ca2 chelation (BAPTA-AM). As well as 
this experiment being set up (3.3.5) the level of intracellular Ca2 was also 
assessed by ion chromatography (3.3.3.2). The mechanism of ion 
chromatography is based on the elution time, or time it takes for the ion to 
move through the column, varying for each ionic species as they elute from 
the column separately (with increasing ionic strength of the eluent). The 
concentration of ions moving through the column at a particular time is 
represented by the height and the breadth of the peaks and can be 
correlated to the concentration of a particular species, such as Ca2 for 
example, (Fig.4.1B) in the sample solution. Fig.4.1 A&B display the typical 
data output from an ion chromatography run for standard curve preparation.  
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Figure 4.1 Standard curves of six cations from an ion chromatography. (A), 
represents the 6 separate ions from a known sample solution. (B), Ca2 standard 
curve of absorbance in linear function with respect to µg/ ml concentration. 
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Figure 4.2 Ca2 and Mg2+ concentrations are increased in PNT2 cells treated with 
leukaemia cancer cell derived-MVs. (A), shows the concentration of Ca2 and Mg in 
µg/ml in blank control. (B), is the concentration of Ca2 and Mg2+in µg/ml in PNT2 
untreated control cells. (C), shows the concentration of Ca2 and Mg2+ in PNT2 cells 
treated with Jurkat cell derived-MVs. (D) is a summary of concentration levels 
ofCa2 and Mg2+ upon addition of Jurkat MVs, together with blank control and PNT2 
untreated control cells.***P<0.001, **P<0.01, *P<0.05. 
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Measuring the level of six cations; lithium, sodium, ammonium, Potassium, 
Magnesium and calcium in blank control, untreated PNT2 cells and PNT2 
cells treated with leukaemia cell derived-MV which was measured by ion 
chromatography. Double distilled water was used here as a blank control 
that was added onto the cells pellets, both in control cells and treated 
panels before lysing them. This result demonstrates that PNT2 cells 
exposed to Jurkat cell derived-MVs causes changes in the cytosolic 
concentrations of sodium, potassium, magnesium and calcium, changes in 
calcium appearing to be most significant. The cytosolic concentration of 
calcium in PNT2 control, untreated cells (Fig.4.2 B) was 10. 2145 µg/ml 
after blank correction and increased to 22.5283µg/ml (Fig.12.C), in PNT2 
cells were treated with Jurkat cell derived-MVs. The difference between 
control PNT2 cells and treated PNT2 cells, in terms of potassium cations is 
1.5µg/ml and sodium is 200µg/ml. Therefore, 45 min treatment of PNT2 
cells with leukaemia cell derived-MVs causes increased cytosolic 
concentrations of these cations. According to these results, Jurkat cell 
derived-MVs increased the cytosolic concentration of calcium, magnesium, 
sodium, and potassium in PNT2 cells. The results were highly significant, 
with a decreasing order of significance from calcium, magnesium, sodium 
through to potassium (***P<0.001, *P<0.05). This experiment was carried 
out to examine if the changes in concentration of cytosolic cations occur 
after adding MVs to the PNT2 cells. Although the concentration of the other 
four cations increased upon addition, the result was highly significant for 
cytosolic calcium ions only (**P<0.01).  This could be an indication of 
phenotypic changes in PNT2 cells treated with blood cancer cells-MVs that 
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is probably associated with remodelling of calcium influx pathways. MVs 
caused an increases of cytosolic magnesium ions in the experiment panel 
and the result was significant (*P<0.05). The correlation between cytosolic 
concentrations of these cations especially calcium and EMT are well 
documented in epithelial cells. Epithelial growth factor induces EMT in 
epithelial cells in the presence of high level of calcium in the cytoplasm of 
the target cells. Following on from this it was important to find out if Jurkat 
cell derived-MVs cause EMT in PNT2 cells by increasing the cytosolic 
calcium concentration.  
 
4.2.2 Blocking intracellular calcium 
In order to determine the effect of cytosolic calcium concentration on EMT, 
a calcium chelator (BAPTA-AM) was used to chelate intracellular calcium in 
PNT2 cells treated with blood cancer MVs. The experiment was set up the 
same way as before (section 3.3.5), except that the PNT2 cells were pre-
incubated with BAPTA-AM. Before the PNT2 cells were exposed to blood 
cancer MVs, the cells were seeded for 24 hrs, and then washed twice with 
serum-free medium. BAPTA-AM (0.2µM) was then added to each well 
except the control group. The plate was then incubated for 15 min and then 
washed three times with serum-free medium. Fresh complete growth 
medium was added into each well plate together with 30µg/ml of Jurkat cell 
derived-MVs into the experiment panels. 
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Figure 4.3 Fluorescence microscopic analysis of PNT cells pre-treated with BAPTA-
AM exposed to leukaemia cell derived-MVs acquire phenotypic changes. (A), 
Expression level of E-cadherin on control, untreated PNT2 cells. (B), Nuclear staining 
using DAPI- Vectashield. (C), Combination of (A) and (B). (D), Expression level of E-
cadherin on PNT2 cells treated with Jurkat MVs. (E) Nuclear staining using DAPI- 
Vectashield.  (F) Combination of (A) and (B).  (G) pre-treated with BAPTA-AM and then 
exposed to 30 µg/ml leukaemia cell derived-MVs. (H), Nuclear staining using DAPI-
Vectasheild. (I), Combination of (G) and (H). (J), Expression level of E-cadherin on 
PNT2 cells treated with BAPTA-AM. (K), Nuclear staining using DAPI-Vectashield. (L), 
Combination of (J) and (K). 
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Fig.4.3 demonstrates the effect of cytosolic calcium concentration on PNT2 
cell morphology and E-cadherin protein expression. In this experiment prior 
to exposure of PNT2 cells to Jurkat cell derived-MVs, the cells were 
incubated with BAPTA-AM. Leukaemia cell derived MVs caused EMT in 
PNT2 cells, as we can see (Fig.4.3 G and I, compared to untreated controls, 
Fig. 4.3, A and C),PNT2 cells becoming stretched out, no longer showing 
the normal, uniform, round-shaped phenotype (classical epithelial sheet) of 
epithelial cells. However, although surface expression levels of E-cadherin 
had not diminished, there now was more of a cytoplasmic localization of E-
cadherin implying an inhibition of calcium-mediated recycling (endocytosis 
and exocytosis) of E-cadherin. The morphology of the cells was however 
still altered (as for the Jurkat MV-treated PNT2 cells) acquiring a stretched 
out, more mesenchymal-like shape, suggesting partial EMT. PNT2 cells 
treated with BAPTA-AM only, maintained their morphology (Fig.4.3 J and 
L), but E-cadherin molecules appeared mainly in the cytosol of the target 
PNT2 cells. According to these findings, Jurkat MV-derived increased in 
cytosolic calcium might probably constitute one of the elements in the EMT 
process of normal prostate epithelial cells. As Ca2+-mediated MMPs 
cleavage of the extracellular domain of E-cadherin is well described in 
EMT(187) and both MMP9 and Ca2+ are carried by MVs, this is an aspect 
of MV-mediated EMT investigated later in this chapter. 
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4.2.3 Transformed PNT2 cells (tPNT2) cells acquire EMT at the 
expense of cell proliferation 
In this experiment I compared the proliferation and differentiation rate of the 
PNT2 and tPNT2 cells in a time-dependent manner. Fig.4.4 shows the 
microscopic analysis of control, untreated  PNT2 cells and PNT2 cells 
treated with 30 µg/ml leukaemia cell derived-MVs. Fig.4.4 A,B and C 
shows  the typical features of normal epithelial cells which look round, 
globular and tend to grow together as an epithelial sheet.The proliferation 
rate of these control, untreated PNT2 cells was normal as by day 5 they 
appeared to be confluent. Fig.4.4 D, E and F demonstartes the role of 
leukaemia cell derived-MV on the phenotypic appearance of and 
proliferation rate of PNT2 cells. These cells have  lost their epithelial 
characteristics, cells in the experiment panel (F) compared to untreated 
controls (C) looking stretched out and no longer growing together. 
Furthermore, to compare the proliferation rate of control and treated cells, it 
can be clearly seen that epithelial cells treated  with Jurkat MVs proliferate 
significanty less than control untreated PNT2 cells (Fig. 4.4 G). Reduction 
in cell proliferation (which was not apparent until after the first 48hrs) might 
be due to the differentiation of PNT2 cells. In fact, Epithelial cells treated 
with T cell leukaemia derived-MVs differentiate into mesenchymal-like cells 
at the cost of their proliferation.The effect of Jurkat MVs on PNT2 
proliferation and differentiation begin from day three onwards  and reached 
a maximum by day five. 
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Figure 4.4 Jurkat cells derived-MVs causes significant reduction of cell 
proliferation in normal prostate epithelial cells. (A), shows the morphology of 
control, untreated PNT2 cells on day zero, day 3 (B) and day 5 (C).The morphology 
of PNT2 cells treated with leukaemia cell derived-MVs is shown on day zero (D), 
day 3 (E) and day 5 (F). (G), Summary of PNT2 cell proliferation and differentiation 
upon addition of Jurkat MVs, together with controls. *P<0.05,**P<0.001,  
***P<0.001. Scal bar= 200µm.  
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4.2.4 Serum starved tPNT2 cells resist apoptotic signals 
Having shown Jurkat MVs to appear to induce EMT in benign, prostate, 
PNT2 cells, the aim now was to see how these Jurkat MV treated PNT2 
(tPNT2) cells react to 48 hrs serum starvations, compared to normal 
prostate epithelial cells. An Apoptotic assay was carried out using Guava 
Nexin (Millipore) according to the manufacturer’s instructions, using Guava 
EasyCyte technology. Apoptosis is a highly organised process of 
programmed cell death which ensures normal development and 
homeostasis of multi-cellular organisms. This process provides a balance 
between cell proliferation and differentiation and removal of unwanted cells.   
Fig. 4.5 A, B show the Guava EasyCyte analysis of apoptosis, summarised 
in Fig. 4.5 C and D. PNT2 cells exposed to serum starvation for 48 hrs lose 
the asymmetry of their cell membrane phospholipids resulting in the 
exposure of phosphatidylserine (PS) on the outer leaflet of the plasma 
membrane, which binds to annexin V (X-axis) and 7-AAD a fluorescent 
compound with strong affinity for cellular DNA (Y-axis). The normal 
epithelial cells (Fig. 4.5 A), exhibited more late apoptosis (15%) following 
48 hrs serum starvation than transformed PNT2 (Fig. 4.5 B) cells, 
exhibiting just 7.5% late apoptosis. Similarly, while the viability of PNT2 
serum starved cells fell to 84%, it only fell to 90% for Jurkat MV treated 
PNT2 cells. 
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Figure 4.5 Normal prostate epithelial cells treated with Jurkat MVs show 
resistance against apoptosis under stress conditions (A), Apoptotic assay of control 
untreated PNT2 cells exposed to serum starvation using Guava EasyCyte. (B), 
Apoptotic assay of tPNT2 cells using Guava EasyCyte analysis. (C), shows the 
summary of cell viability of PNT2 and tPNT2 cells under stress condition for 48 hrs. 
(D), shows the % of late apoptotic PNT2 and tPNT2 cells after 48 hrs exposure to 
serum starvation. 
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4.2.5 tPNT2 cells show significantly reduced sensitivity to cytotoxic 
agent 
This assay was set up to address the functional consequences of EMT 
induced by Jurkat cell derived-MVs. To begin with, any difference in 
sensitivity to a cytotoxic drug, such as docetaxel, was compared between 
Jurkat MV treated PNT2 and normal PNT2 cells. This assay has been 
applied to preclinical screening of new anti-neoplastic agents, cytogenetic 
analysis of human tumour specimens, and the identification of growth 
factors. Essentially PNT2 cells were treated with anti-cancer drug for 48 hrs 
and then viability and status of apoptosis determined as described before 
using Guava Nexin.  PNT2 cells (Fig.4.6 A), exhibited significantly higher 
susceptibility to docetaxel than Jurkat MV treated cells PNT2 (Fig.4.6 B) 
cells, showing 15% of the population (PNT2) in late apoptosis as opposed 
to 7.5 % (tPNT2 cells). Looking at cell viability it is clear that the Jurkat MV 
treated PNT2 cells are more resistant to the effect of docetaxel, viability 
having only reduced to 70% compared to 60% with control untreated PNT2 
cells. Furthermore, this resistance to a chemotherapeutic drug is a clear 
indication of one of the functional consequences of EMT and interestingly, 
the mechanism bringing about such changes is normally through genetic or 
epigenetic changes. 
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Figure 4.6 Transformed PNT2 cells showed resistance upon 48 hrs treatment 
with docetaxel (10 µM). A), Apoptotic assay of control untreated PNT2 cells 
using Guava Easy Cyte technique. (B), Apoptotic assay of Jurkat MV treated 
PNT2 cells using Guava EasyCyte analysis. (C), shows the summary of cell 
viability of PNT2 and Jurkat MV treated PNT2 cells control untreated cells and 
PNT2 and tPNT2 cells treated with 10µM docetaxel for 48 hrs. (D), shows 
the % of late apoptotic PNT2 and tPNT2 cells after 48 hrs treatment with 
docetaxel.  
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4.2.6 PNT2 cells treated with Jurkat MVs show resistance to docetaxel 
This experiment was carried out to observe the cytotoxity effect of 
docetaxel on PNT2 cells and tPNT2 cells using 7-AAD staining and 
fluorescence microscopy. 7-AAD is a ready-to-use solution for the exclusion 
of non-viable cells in fluorescent microscopic analysis. This dye can pass 
through the membrane of damaged cells but not through intact cell 
membranes of normal, viable cells. It is a fluorescent intercalator with a 
high affinity for DNA.  In this study, PNT2 cells treated with docetaxel 
showed greater vulnerability in their cell membrane compared to tPNT2 
cells. Fig.4.7 shows fluorescent micrographs of PNT2 cells (Fig. A, B, C) 
and tPNT2 (Fig.4.7 C, D, E) after exposure to 10 µM docetaxel for 48 hrs. 
Normal prostate epithelial cells treated with docetaxel for 48 hrs (Fig.5.7B) 
shows more cells with damaged plasma membrane compared to tPNT2 
cells (Fig.4.7 E). Resistance to chemotherapy demonstrates an important 
functional consequence of EMT as demonstrated in tPNT2 cells.  PNT2 
cells, as well as acquiring morphological changes after treatment with 
leukaemia cell derived-MVs, show increased resistance against apoptotic 
signals. This anti-apoptotic effect in tPNT2 cells in fact demonstrates that 
leukaemia cell derived-MVs not only induced phenotypic changes in PNT2, 
but presumably transferred certain cancer cell elements into PNT2 cells 
which capable of interfering with apoptotic signalling pathways responsible 
for the regulation of apoptosis in normal prostate epithelial cells.  
 
 
 
Results 
 
 
131 
 
 
 
 
 
 
 
  
D E F
A B C
PNT2
tPNT2
Cells treated with 10 µM Docetaxel
7-AAD
7-AAD 7-AAD
7-AAD
Figure 4.7 tPNT2 cells show reduced nuclear staining (7-AAD) indicating 
reduced late apoptosis and greater resistance to Docetaxel compared to 
control, untreated PNT2 cells. (A), Phase contrast image of PNT2 cells 
treated with 10 µM docetaxel. (B), PNT2 cells treated with docetaxel and 
stained with7-AAD red dye. (C), combination of (A) and (B). (D), Phase 
contrast image of tPNT2 cells treated with 10 µM docetaxel. (E), tPNT2 cells 
treated with docetaxel and stained with7-AAD red dye. (F), combination of 
(D) and (E). Scale bar is 50µm. 
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4.2.7 Enzyme Liked Immuosorbent Assay confirmed significant level 
of MMP9 expression in tPNT2 cells 
MMP9 is a member of the family of structural and functional related 
endopeptidases. This enzyme belongs to the zinc-metalloproteinase family 
involved in the degradation of the extracellular matrix in normal 
physiological processes such as bone development and wound healing, but 
also in pathological conditions such inflammation and cancer metastasis. In 
this study I focused on the expression of this specific matrix enzyme, 
because it is involved in the development of malignant tumour including 
invasion of the tumour microenvironment, abnormal growth, angiogenesis 
and cancer metastasis. Here, I was trying to determine whether Jurkat MVs 
cause EMT in PNT2 cells due to the transfer of some oncogenic factors to 
the target cells. MMP9 was measured from the cell culture supernatant of 
PNT2 and tPNT2 cells. The intention was thereby to examine further the 
functional consequences of EMT in tPNT2 cells, in this case by measuring 
MMP9. tPNT2 cells express high level of MMPs (Fig.4.8 B and E) 
compared to control, untreated PNT2 cells.  MMPs play a significant role in 
the occurrence of cancer, especially in the remodelling of tissue that occurs 
with the invasion of prostate tumours.  This result in fact strongly suggests 
that PNT2 cells treated with leukaemia cell derived-MVs express 
significantly high levels of this degrading enzyme compared to control, 
untreated PNT2 cells and this could confirm one of the functional 
consequences of EMT induced by Jurkat MVs on target prostate cells.  
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Figure 4.8 tPNT2 cells express a significantly high level of MMP9 as measured by 
ELISA. (A), MMP 9 standard curve in linear function of absorbance against 
concentration (µg/ml). (B) Expression level of MMP9 in normal PNT2 and tPNT2 
cells. (C), Mean absorbance of ELISA for PNT2 and tPNT2 cells using FLUOstar 
Omega plate reader. (D), Fluorescence microscopy image of MMP9 in PNT2 cells, 
and (E), Fluorescence microscopy image of MMP9 in tPNT2 cells.*P<0.05, 
**P<0.01, ***P<0.001, Scale bar is 50µm. 
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4.2.8 Cell Cycle analysis shows significant number of tPNT2 cells 
arrested in the G2 phase of the cell cycle 
In this experiment I tried to determine another of the functional 
consequences of EMT in tPNT2 cells at the DNA level. This study in fact, 
confirmed that leukaemia cell derived-MVs cause EMT through the 
dysregulation of the cell cycle in tPNT2 cells. Fig.4.9 A and B show the 
DNA contents of PNT2 cells in each stage of the cell cycle and the pattern 
seems to follow a normal distributions (G0/G1=41%, S=20% and 36%). 
Fig.4.9 C and D show the percentage of cell distribution for tPNT2 cells. 
The pattern in tPNT cells does not appear normal by any mean. Fig.4.9 D  
shows only 11% of the total tPNT2 cells to be in G0/G1. Percentages of 
cells in the S phases of both PNT2 and tPNT2 cells are almost the same, 
20% and 19% respectively but the percentage of tPNT2 cells in G2/M 
phases of the cell cycle is significantly high (69%) compared to PNT2 cells 
(36%). The G2 phase is one the several checkpoint in the mammalian cell 
cycle at which the progression of a cell to the next stage in the cycle can be 
halted until conditions are favourable. Therefore, the most important 
function of the G2 phase is to ensure chromosomes are accurately 
replicated without any mistakes. Accordingly a high percentage of tPNT2 
cells were found to be arrested in G2/M which in fact means exposure of 
normal prostate epithelial cells to leukaemia cell derived-MVs causes DNA 
damage of the target PNT2 cells. 
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Figure 4.9 High numbers of tPNT2 cells are arrested in the G2/M phase of the cell cycle. 
(A) Shows normal histogram pattern of PNT2 cells in the G0/G1, S and G2/M phases of 
the cell cycle. (B), show the DNA content of PNT2 cells in each stage of the cell cycle. (C) Is 
the histogram pattern of tPNT2 cells in the G0/G1, S and G2/M phases of the cell cycle. (D) 
Indicates DNA content of tPNT2 cells in each stage of the cell cycle. (E) Shows the 
summary of the % of PNT2 and tPNT2 cell distributions in each phase of the cell cycle. 
E *** 
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4.3 Summary 
The first results chapter of this thesis concentrated on the morphological 
and markers of EMT that I was able to observe could be induced in prostate 
cells upon exposure to T cell leukaemia-derived MVs. Having made this 
important observation the second results chapter has set about 
understanding the causes and biological consequences of EMT in normal 
prostate epithelial cell lines (after exposure to Jurkat-derived MVs). The 
cause of MVs-induced EMT in the epithelial cells was partially answered in 
the first part of the result section and in this results chapter I studied the 
role Ca2+ signalling plays in PNT2 cells treated with Jukat MVs that 
acquired EMT. According to this finding, cytosolic Ca2+ concentration was 
increased (Fig.4.3) in PNT2 cells treated with blood cancer cell MVs. 
However, the increased cytosolic Ca2+ concentration causes a likely 
endocytosis of E-cadherin (Fig.4.3) from the cellular junction into the 
cytoplasm of PNT2 cells that have been treated with Jurkat MVs. This 
internalisation of junctional protein might be one of the reasons for the 
epithelial cells to grow apart from each other and loss their epithelial 
characteristics. In order to answer these questions, a series of 
immunocytochemistry assays and ELISA were performed accordingly. 
According to these results, tPNT2 cells no longer behave like normal 
prostate epithelial cells and also PNT2 cells that acquired EMT show more 
resistance against apoptotic signals under stress conditions such as serum 
starvation and chemotherapies (Fig.4.5, 4.6). 
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 Results obtained by MMP9 ELISA confirmed that epithelial cells exposed 
to leukaemia cell derived-MVs express high levels of degrading enzyme 
(Fig.4.8) compare to normal PNT2 cells. This can be a clear indication that, 
MVs derived from cancer cells are responsible for horizontal transfer of 
some oncogenic protein in the recipient cells as would be indeed from 
transformed prostate cancer cells to normal prostate cells. Furthermore, 
results from the cell cycle analysis show that, a high proportion of the cell 
population in the transformed PNT2 cells are arrested in the G2 phase of 
the cell cycle (Fig.4.9 C compared to normal prostate epithelial cell lines 
Fig.4.9 A). Therefore, according to this study I postulated that, leukaemia 
cell derived-MVs induce the cancerous type of EMT in normal prostate 
epithelial cell lines. This influence of MVs on epithelial cells can be clearly 
due to its bioactive molecules which they may inherit from their parental 
blood cancer cells.  
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4.6 Schematic diagram of causes and functional consequences of 
EMT induced by leukaemia cell derived-MVs on PNT2 cells 
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5. Non-Small Lung Cancer Cell (A549) 
microvesicles (tMVs) affect normal lung 
fibroblast cells (MRC5) in the tumour 
microenvironment 
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5.1 Introduction 
Non-Small Cell Lung Cancer (NSCLC) cells are adenocarcinomas of 
human alveolar basal epithelial cells. It is the leading cause of cancer 
related death all over the world. The tumour microenvironment is believed 
to have a significant influence on cancer cell growth, progression, and 
metastasis and on the treatment outcome. These influences are mainly due 
the ability of the microenvironment to change its landscape in response to 
stress signals. Fibroblasts are resident stromal cells that function as 
supportive cells in tissue organ. During wound healing, chronic 
inflammation and malignancy these cells become activated. The central 
feature of fibroblast activation, upon which they are known as 
myofibroblasts, is the expression of α-SMA protein. In this study I tried to 
determine the role of NSCLC cell-(A549-) derived microvesicles (tMVs) on 
normal lung fibroblast cells (MRC5). Non-Small Cell Lung Cancer cell 
supernatant was used as a source of tMVs for the treatment of MRC5 
target cells. I aimed to test the various concentrations with different time 
exposures of tMVs on the MRC5 cells. Lung fibroblast cells were labelled 
with anti-α-SMA antibody and an anti-Fibroblast Growth Factor (FGF) 
antibody. The analysis was carried using Guava EasyCyte technology, 
fluorescence microscopy imaging and the FLUOstar Omega plate reader. 
In the second attempt MVs were isolated from the supernatant of the 
activated form of fibroblasts and labelled with anti-α-SMA antibody. MRC5 
cells were co-cultured with myofibroblast-derived MVs for 5-7 days 
incubation periods and then assessed for FGF and α-SMA expression. 
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Statistical comparisons on data between the two groups of MRC5, 
untreated, control cells and MRC5 cells treated with tMVs were performed 
using GraphPad Prism 5 software. The differences were considered to be 
significant when *P<0.05.  
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5.2 Results 
5.2.1 MRC5 cell treated with tMVs acquire phenotypic changes as 
observed by phase contrast microscopy 
Upon treatment of MRC5 cells with 50 µg/ml A549-derived tMVs, there was 
a clear phenotypic change in the cells (Fig.5.1). Control untreated MRC5 
cells (Fig 5.1A) exhibit the normal characteristics of primary lung fibroblasts 
including uniformly elongated and stretched cells, whilst MRC5 cells were 
treated with A549 cell derived tMVs (Fig.5.1B), showed loss of fibroblast 
features and were no longer uniformly elongated having now acquired 
irregular shape. However, in order to find out whether addition of A549 
tMVs to the MRC5 cells lead to the activation of these fibroblasts, I labelled 
the MRC5 cells to ascertain α-SMA expression at the protein level as this is 
a specific marker for fibroblast activation. The aim, therefore, was to 
demonstrate the role of A549 tMVs on fibroblast activation at the molecular 
level by monitoring the expression of the cytoskeletal protein, α-SMA, using 
immunocytochemistry. Alpha-smooth muscle actin, as a specific marker for 
myofibroblasts, plays a central role in myofibroblast contraction. 
Myofibroblasts are capable of regulating tissue fibrosis through the action of 
their contractility. At the genetic level, a number of transcription factors are 
believed to be involved in the expression of α -SMA such as the DPP 
homologue 2/3, myocardin-related transcription factors A/B (MRTF-A/B) 
and CCAAT/enhancer-binding protein beta (CEBP-β); high expression of 
miR-21 is another contributor of fibroblast activation in lung tissue.   
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Figure 5.2.1 A549 tMVs alter the morphology of MRC5 cells. (A), MRC5 
control, untreated cells. (B), MRC5 cells treated with A549 tMVs. Scale bar 
is 50µm. 
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5.2.2 MRC5 cells treated with A549tMVs express significantly higher 
levels of α-SMA protein as observed using Guava EasyCyte flow 
cytometer 
In this study MRC5 cells were treated with A549 tMVs for 5 and 7 days and 
then both MRC5 control, untreated cells and MRC5 cells in the experiment 
group were labelled with mAb against α-SMA to confirm fibroblast activation 
(to myofibroblasts).  My aim here was to try to determine firstly whether 
A549 tMVs have any effect on MRC5 cells at the molecular level and 
secondly whether any such effect of tMVs on fibroblasts was dose 
dependent. Therefore, MRC5 cells were treated with two different 
concentrations 30 µg/ ml and 50µg/ ml of A549 tMVs for 5 and 7 days. The 
percentage of α-SMA protein expression is significantly higher in the MRC5 
cells treated with 50µg/ml A549 tMVs for 7 days compared to cells given 
30µg/ml for 5days and control, untreated MRC5 cells (Fig.5.2). This study 
shows that the effect of A549 tMVs on MRC5 activation is dose and time 
dependent.  
Whereas the percentage of α-SMA expression in the panel treated panel 
with 30 µg/ml is about 6% greater compared to cells under basal conditions 
(*P<0.5), exposing MRC5 cells to 50µg/ml tMVs for 7 days increased the 
expression of the myofibroblast marker on the MRC5 cells by a highly 
significant  60% (***P<0.001). 
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Figure 5.2.2 MRC5 cells treated with A549 tMVs express significantly higher 
levels of α-SMA. (A), Expression level of α-SMA in MRC5 cells treated with 30 
µg/ml of A549 tMVs. (B), Expression level of α-SMA protein on MRC5 cells 
treated with 50µg/ml of A549 TMVs. (C), Summary of expression level of α-SMA 
on MRC5 cells treated with A549 TMVs.(-) Percentage of expression of α-SMA in 
MRC5 control, untreated MRC5 cells. (-) Percentage of expression of α-SMA in 
MRC5 treated cells with 30 µg/ml of A549 tMVs. (-) Percentage of expression 
inMRC5 cells treated with 50µg/ml of A549tMVs. *P<0.05, **P<0.1, ***P<0.001.  
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5.2.3 MRC5 cells treated with A549 tMVs express higher level of α-
SMA as observed using fluorescence microscopy 
As before, fibroblasts were treated with A549 tm’s, this time just at the 50 
µg/ml dose for 5 and 7 days (Fig.5.4.3 D, F and G,I), and the expression of 
α-SMA protein compared to the MRC5 control, untreated cells (Fig. 5.4.3 A 
and C) using fluorescence microscopy. According to these experiments, 
MRC5 cells treated with 50µg/ml of tm’s for 7 days expressed significantly 
high levels of -SMA protein compared to cells treated with 50 µg/ml of 
A549 tm’s for just 5 days (and control, untreated cells) as determined by 
fluorescence microscopy. This experiment demonstrates that A549 cells, 
through the interactions of their MVs, can have an influence on their 
surrounding ECM, including primary lung fibroblasts which may become 
activated, expressing greatly increased levels of -SMA. 
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Figure 5.2.3 MRC5 cells express high levels of α-SMA protein after 
treatment with A549 tMVs using fluorescence microscopy. (A), expression 
level of α-SMA protein in MRC5 control, untreated cells. (B) Nuclear staining 
using DAPI-Vectashield. (C), Combination of (A) and (B). (D), Expression level 
of α-SMA protein in MRC5 cells treated with 50µg/ml A549 tMVs for 5 days. 
(E), Nuclear staining using DAPI-Vectashield. (F), Combination of (D) and (E). 
(G) Expression level of α-SMA protein in MRC5 cells treated with 50 µg/ml 
of A549 tMVs for 7 days. (H), Nuclear staining using DAPI-Vectashield. (I), 
Combination of (G) and (H). The scale bar is 200µm. 
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5.2.4 A549 tm’s increase the expression level of Fibroblast Growth 
Factor-1 in primary lung fibroblasts as determined using the Guava 
EasyCyte flow cytometer 
Another parameter that was deemed interesting to monitor in fibroblast 
activation by A549-derived tMVs was the expression of Fibroblast Growth 
Factor-1 (FGF-1). FGFs are multifunctional proteins that have been shown 
to play important roles in the process of proliferation and differentiatio n of a 
variety of cells and tissues. Therefore, in the following experiments where 
primary lung fibroblasts treated with A549 tMVs acquired different 
morphological characteristics Iabelled these fibroblasts with anti -FGF-1 
mAb to monitor its expression, before and after treatment with A549 tMVs 
using standard immunocytochemistry. Fig.5.4.4 A shows the 
immunolabelling of MRC5 cells with anti-FGF-1 antibody before and after 
treatment with tMVs. The result was analysed by flow cytometer showing 
unlabelled cells (-), control untreated MRC5 cells (-), and MRC5 cells 
treated with A549 tMVs (-).  Accordingly, primary lung fibroblasts treated 
with A549 tMVs expressed more FGF-1protein than control, untreated 
MRC5 cells. Fig.5.4 B is the summary of FGF expression in MRC5 control 
untreated cells and MRC5 cells were treated with 50µg/ml of A549 TMVs 
for 5 and 7 days. According to this finding, 5 days treatment of MRC5 cells 
with 50µg/ml of A549 TMVs has little effects on  FGF expression P>0.5, 
However, when the incubation period was increased to 7 days, the 
expression of FGF was increased to a significant level (*P<0.05).  
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Figure 5.2.4 Primary lung fibroblasts treated with A549 tMVs express increased FGF-1 
protein. (A), Expression level of FGF-1 in MRC5 control, untreated MRC5 cells (      ) and 
expression level in MRC5 cells treated with 50µg/ml of A549 tMVs (        ). (B), Summary of 
FGF-1 expression in MRC5 cells treated A549 tMVs. *P<0.05. 
 
 
 
 
5 days 7 days
A
*
B
FG
F-
1
MRC5 + 50µg/ml A549 tMVs (7d)
MRC5, untreated  (7d)
FGF-1
Results 
 
 
150 
 
5.2.5 A549 tMVs increase the expression level of FGF-1 in MRC5 cells 
as observed by fluorescence microscopy 
To ascertain the cellular location of the up regulated FGF-1 on MRC5 cells 
upon treatment with A549 tMVs, I used fluorescence microscopy. Fig. 5.4.5 
shows the immunostaining of MRC5 cells with anti-FGF-1 antibody.  (A, B 
and C) are the results from normal lung fibroblast cells without treatment 
with A549 CD- MVs. (A) the FITC labelled control untreated fibroblast cells 
that shows no FGF expression. (B) Nuclear staining of MRC5 cells under 
basal condition with DAPI Vectashield. (C) Merge image of FITC and DAPI 
in control untreated cells. (D) FITC labelled CD- MVs treated MRC5 cells 
that shows some FGF expression activity. (E) The nuclear staining of 
MRC5 cells in the experiment panel carried out by DAPI vectashield. (F) 
Merge image of FITC and DAPI staining of MRC5 cells treated with CD- 
MVs. According to this experiment, activated form of MRC5 cells that 
induced by non- small lung cancer MVs exhibit more FGF expression 
compare to primary fibroblast cells.  
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Figure 5.2.5 Primary lung fibroblasts express raised levels of FGF-1 after treatment with 
lung carcinoma derived-(A549-) MVs. (A), Expression level of FGF-1 in MRC5 control, 
untreated cells. (B), Nuclear staining with DAPI-Vectashield. (C) Combination of (A) and 
(B). (D), Expression level of FGF-1 in primary lung fibroblasts treated with 50µg/ml A549 
tMVs. (E), Nuclear staining with DAPI-Vectashield. (F), Combination of (D) and (E). Scale 
bar = 200µm. 
 
Results 
 
 
152 
 
5.2.6 Primary lung fibroblasts (MRC5) treated with A549 tMVs release 
MVs with significantly raised expression levels of α-SMA 
Having shown that human lung fibroblasts (MRC5) cells treated with human 
Non-Small Lung Cancer Cell-(A549-) derived MVs become activated, 
expressing raised levels of α-SMA, I now sought to ascertain whether the 
MVs released from such activated MRC5 cells  (after treatment with A549 
tMVs) themselves carry α-SMA protein. Therefore, MRC5 cells were treated 
with 50µg/ml A540-derived tMVs for 7 days, washed once with DMEM 
(serum-free) and then incubated for 12 hrs in DMEM supplied with 10% 
FBS (MV and exosome-free). After 12 hrs, MRC5 cell culture supernatant 
was collected and MVs isolated according to the protocol described 
previously (3.3.1). Isolated MRC5-derived MVs were then labelled with anti-
α-SMA mAb and analysed using the Guava EasyCyte flow cytometer. This 
result clearly demonstrates that treatment of MRC5 cells with A549-derived 
tMVs produces significantly high numbers of MVs (75%-positive) 
expressing α-SMA (Fig. 5.6 E, F), compared to MVs released from control, 
untreated MRC5 cells (20%-positive) (Fig. 5.6 C, D); Fig. 5.6.A and B show 
the negative control in this experiment (0.68%-α-SMA-positive). It is also 
noteworthy that the total amount of protein in MVs derived from activated 
fibroblasts is twice as high (Fig.5.6 H) as MVs derived from fibroblasts 
(Fig.5.6 H). This study in fact confirmed the standard definition of MVs 
which almost all scientists have been emphasising, namely, to paraphrase, 
that ‘the constituents of MVs depend on the nature of their parental cells.’   
The constant release of these subpopulations of MVs from the activated 
fibroblasts along with the A549 cancer cell-derived tMVs is very likely to be 
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able to change the landscape of the tumour microenvironment and help 
towards the invasion of its microenvironment along with intravasation, 
extravasation and metastasis to other distant organs. 
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Figure 5.2.6 Primary lung fibroblasts treated with A549 tMVs release MVs expressing 
high levels of α-SMA. (A and B), unlabeled MRC5 cell-derived MVs. (C and D), Expression 
level of α-SMA protein in control, untreated primary lung fibroblast cell -derived MVs. (E 
and F), Expression level of α-SMA protein on MVs derived from  MRC5 cells treated with 
A549 tMVs. (G), Summary of expression level of α-SMA protein in MVs released from 
activated MRC5 cells. (H), total protein expression level in MVs derived from A549 tMV-
treated MRC5 cells and control, untreated MRC5 cells. ***P<0.001.  
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5.2.7 MRC5 cells were treated with A549 TMVs expressed high number 
of α-SMA positive MVs using fluorescence microscopy 
In this study MVs were isolated from myofibroblasts  and stained with MAb 
against α-SMA cytoskeleton protein using fluorescence microscopy. This 
study demonstrates that MVs derived from the myofibroblasts carrying α-
SMA cytoskeleton protein and I noticed that, there are some factors which 
could affect  the enfluence of  MVs on the target cells. According to this 
results, FBS MVs present in the DMEM medium (Fig.5.4.7 I) casuses 
clamping of activated fibroblasts MVs, this can indeed generally decrease 
the enfluence  of MVs on the target cells and I found from my previous 
study, the results are not included here, the effect of A549 TMVs on the 
primary fibroblasts that were grown in DMEM medium (+FBSMVs) was 
significantly lower than (MV free FBS) medium. This is a clear indication of 
the influence of microparticles such as MVs and exosome that are present  
in growth medium can prevent or to a lesser extend can reduce the effect of 
extra cellular vesicles  on the target cells and this can be explained from the 
(Fig.5.4.7 G), which is the myofibroblasts derived-MVs in DMEM serum 
free, and MVs are present indiviually without clumping. (Fig.5.7H) Activated 
fibroblast derived-MVs in DMEM medium supplied with 10 % FBS (MV free),  
MVs were clumped but to a lsser extent comparing to (Fig. 5.4.7 I), wich is 
activated fibroblasts MVs were added in DMEM medium with 10% 
FBS(+MVs), once MVs were clumped the number of target cells with MVs 
are decrreased as results of their aggregations .available Scale bare= 
200µm.  
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Figure 5.2.7 Activated fibroblast- (myofibroblast-) derived MVs are highly positive for α-
SMA protein as observed by fluorescent microscopy. (A), phase contrast image of MVs 
derived from control, untreated MRC5 cells. (B), Expression of α-SMA on primary 
fibroblast-(MRC5-) derived MVs. (C), Combination of (A) and (B). (D), phase contrast 
image of MVs derived from MRC5 after treatment with 50µg/ml of A549 tMVs. (E), 
Expression level of α-SMA protein on activated fibroblast-derived MVs. (F), Combination 
of (D) and (E). (G), α-SMA labelled MVs from activated fibroblasts (A549 tMV-treated) 
myofibroblasts in serum-free DMEM medium. (H), Alpha-SMA labelled MVs in DMEM 
medium supplied with 10 % FBS (MVs-free). (I) Alpha-SMA labelled MVs in DMEM 
supplied with 10 % (+MVs). Scale bar is 200µm. 
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5.2.8 Transformation of primary fibroblasts with activated fibroblast 
derived-MVs 
Activated fibroblasts or myofibroblasts, in this case MRC5, lung fibroblasts, 
treated with NSCLC-MVs, release two subpopulations of MVs, those that 
stain positive and those that stain negative for α-SMA. In the following 
series of experiments I intended to find which population of MRC5-derived 
MVs, after treatment with A549 tMVs, can in turn alter MRC5 cells. Images 
in Fig.5.4.8 were taken 72 hrs after adding the myofibroblast MVs. The 
boxed area shows MV attachment to MRC5, these MVs being positive for 
α-SMA (Fig 5.4.8 C); a second subpopulation of myofibroblast MVs is also 
seen attached to another MRC6 cells that is negative for α-SMA (Fig.5.8 C  
red arrow). Comparing the interaction of α-SMA-positive and -negative MVs 
with MRC5 cells, it would appear that only α-SMA-positive myofibroblast 
MVs can significantly alter the morphology of MRC5 cells. Such a cell 
(boxed in Fig. 5.4.8 C) appears overgrown, its size seeming at least three 
times bigger than the normal fibroblast; this cell appears ‘transformed.’ Fig. 
5.4.8 D shows MRC5 cells treated with myofibroblast derived-MVs for 7 
days and the now green fluorescence diffused throughout the cells 
demonstrates fusion of labelled MVs with the target cells (Fig. 5.4.8 E, F). 
Normal fibroblast cells generally look stretched out and exhibit front and 
back polarity, this morphological feature being no longer visible in the cell 
that interacted with α-SMA-positive MVs.  
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These findings demonstrate the influence of ‘cancer’ cell-derived MVs on 
the microenvironment, because only MVs derived from the activated 
fibroblasts, as a result of treatment with 50µg/ml of tMVs, could cause 
‘transformation’ of MRC5 cells. 
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Figure 5.2.8 α-SMA-positive MVs fuse with the plasma membrane of primary lung 
fibroblasts, MRC5. (A), Phase contrast image of MRC5 cells treated for 3d with 
myofibroblast derived-MVs. (B), α-SMA-positive myofibroblast derived-MVs attached to 
primary lung fibroblasts. (C), Combination of (A) and (B). (D) MRC5 cells treated for 7d 
with α-SMA-positive MVs derived from the activated fibroblast cells. (E) Expression level 
of α-SMA protein. (F) Combination of (D) and (E). Scale bar is 200µm. 
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5.2.9 MRC5 cells were treated with myofibroblasts derived-MVs 
expressed high level of α-SMA using fluorescent microscopic analysis 
In section 5.2.8 I showed that myofibroblast MVs expressing α-SMA 
appeared to ‘transform’ primary lung fibroblasts. To further confirm this, the 
following experiments were conducted to look for the concomitant 
expression of α-SMA as a measure of the observed ‘transformed’ 
morphology. MRC5 cells were treated with 50 µg/ml of myofibroblast-
derived MVs for 7 days then stained against α-SMA protein to detect the 
expression of this cytoskeletal protein. This study clearly demonstates that 
MVs derived from activated fibroblast cells, likely carrying certain elements 
of cancer cells (inherited from parent cells tha t were treated with A549 
carcinoma cell MVs and which activated primary lung fibroblasts into 
myofibroblasts (activated fibroblasts). The activation of these mesenchymal 
cells were confirmed by the phenotypic changes of the target fibroblasts 
and also at the molecular level by the expression of α-SMA protein on the 
recipient MRC5 cells. This study therefore demonstrates the influence 
carcinomas have on their microenvironment. It would thus appear that 
carcinomas are able to govern the landscape of of the tumour 
microenvironment through the release of MVs. The transformation of 
primary fibroblasts into myofibroblasts was started by the release of  A549 
cell-derived MVs and then these activated fibroblasts act as a cofactor to 
increase the process of fibroblast activation and also participate in the 
regulation of the tumour microenvironment. 
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Figure 5.2.9 MRC5 cells treated with myofibroblast-derived MVs express significantly 
high levels of α-SMA protein as observed by fluorescence microscopy. (A), Expression 
level of α-SMA protein in MRC5 cells. (B), Nuclear stainingwith DAPI-Vectashield. (C), 
Combination of (A) and (b). (D), Summary of the expression level of α-SMA cytoskeleton 
protein in MRC5 cells treated with 50µg/ml of myofibroblast-derived MVs (red bar) and 
50 µg/ml primary lung fibroblast-derived MVs (blue bar). Scale bar is 200 µm, 
***P<0.001.  
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5.3 Summary 
This study was performed to determine the influence of carcinoma cell-
derived (A549-) MVs on primary lung fibroblast cells and also to have an 
insight into the mechanism of interaction between tMVs and the MRC5, 
primary, human fibroblast target cells. According to these findings, MVs 
derived from the Non-Small Cell Lung Cancer cells; result in major 
phenotypic changes of primary lung fibroblast cells, causing them to 
become activated fibroblast cells, known as myofibroblast cells. The 
transformation of fibroblast cells into myofibroblast cells can be confirmed 
by the expression of a myofibroblast marker, α-SMA, and a cytoskeletal 
protein in the target cells. In this study, the expression level of the 
myofibroblast marker was measured in both fibroblast cells under basal 
conditions and in fibroblast cells treated with tMVs using various 
technologies including the Guava EasyCyte flow cytometer (Millipore), 
fluorescent microscope (Olympus IX81) and FLUOstar Omega plate reader. 
FGF-1 expression levels were also measured in both control untreated 
fibroblast cells and tMV-treated cells. In later experiments I attempted to 
gain an insight into the nature of the MVs derived from the activated form of 
the fibroblast cells collected from MRC5 cells after treatment with tMVs. 
Further work was also performed to examine the influence of MVs derived 
from the activated form of fibroblast cells on the primary fibroblast cells. The 
results obtained from this study demonstrated that only those populations of 
MVs that were positive for α-SMA cytoskeletal proteins were capable of 
fibroblast transformation into myofibroblast cells. 
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5.4 Schematic diagram of tMVs inducing fibroblast activation 
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6. Discussion 
6.1 Limitations of MV analysis 
Microvesicles (MVs) are small membrane enclosed vesicles released into 
the extracellular environment by most mammalian cell types under normal 
and pathological conditions. Microvesiculation is observed both under in 
vitro and in vivo conditions and its process does not affect cell viability (188).  
MVs are generated by an external budding from the cell surface and are 
detected in a variety of biological fluids such as blood, urine, spinal cerebral 
fluids, saliva and ascites, and MVs play crucial roles in intercellular 
communication (189). Apart from participation in physiological cell signalling, 
there are strong suggestions that these vesicles can be useful in novel 
treatment modalities; for example MVs are considered as potential carriers 
of therapeutic drugs that could elicit anti-tumour responses.   
The advances in research on MVs in cancer therapeutics are extraordinary 
(190). However, there are major concerns regarding an efficient and 
standardized method of MV isolation, purification, concentration, size 
measurement and molecular content. These issues in fact limit the capacity 
of MVs in the clinical diagnostic and prognostic fields for a variety of 
diseases, and certainly in the cancer therapeutics field (191). To overcome 
this, a reliable and re-producible MV isolation/characterization protocol is 
still needed. This will also enable accurate genomic, proteomic and 
lipidomic characterization carried out on a variety of cell types including 
blood cells, epithelial cells, endothelial cells, muscles cells, and neuronal 
cells both under normal and different pathological conditions such as 
systemic, inflammatory conditions and cancers.  MV characterization in fact,  
Discussion 
 
 
166 
 
is a major challenge and none of the available techniques including flow 
cytometry can reliably distinguish the size of MVs and also define them at 
the single vesicle level.  
Fig.3.1 in the results section presents the flow cytometric analysis of MVs 
using the Guava EasyCyte instrument.  This flow cytometer enables MVs to 
be characterized on the basis of the spectral properties of the fluorescence 
signal that defines the morphology and specific sorting. Analysis of MVs is 
achieved through the hydrodynamic focusing where the suspended cells 
move through a compressed channel until they encounter the laser. The 
emitted scatter and fluorescence is captured and measured by a detector 
which is located in front of the laser. The intensity of light is reported as 
forward scatter (FSC) and side light scatter (SSC). The quantity of forward 
scatter light is proportional to diameter and side scatter light is related to the 
morphology of the MVs. The heterogeneity of MVs is determined by the 
filter that captured the appropriate range of the emission peak. This 
scattering requires the use of calibration beads of known size and numbers 
to identify the heterogeneous population of MVs.  
Fig.4.2 A&B defines this heterogeneous population of MVs labelled with 
fluorescence labelled annexin V. Annexins constitute a family of 
phospholipid binding proteins that are predominantly located on the 
cytosolic face of the plasma membrane of healthy cells. During 
microvesiculation phosphatidylserine loses its asymmetric distribution in the 
phospholipids’ bilayer and translocates to the extracellular leaflet of the 
plasma membrane where its presence can be detected by fluorescence 
labelled Annexin V. Jurkat (T cell leukaemia) MVs were isolated and 
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analyzed by fluorescence activated cell sorting (Fig.3.2 A), and expression 
of Annexin V was analyzed separately (Fig.4.2 B). From the fluorescent 
staining results that were carried out by FACS, 60 % of the MV population 
was positive after the first wash of the sample labelled with Annexin V, a 
level which increased to 66% after the sample was washed a second time. 
A marked reduction on the total number of MVs was noticed after the 
second centrifugation. Increased percentage of Annexin V positive MVs 
after the second wash can be due to the degradation of Annexin V negative 
MVs which happened after the second centrifugation. It appears that, 
translocation of PS to the outer membrane bilayer probably protects MVs 
from degradation. However the question yet to be answered is the  nature of 
the remaining 36-40% of these particles which were gated in the area 0.1 - 
1µm on the FSC region. There is evidence in the literature suggesting that 
around 30-35% of MVs do not possess PS on their membrane. Therefore, it 
has become a high priority to find an alternative marker for greater 
specificity and sensitivity than Annexin V for MVs characterization. The 
basis of this section of the discussion about MV characterization is to 
consider that the results obtained from this experiment are purely due the 
effect of a heterogeneous population of T-lymphocyte cancer cell derived 
MVs. 
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6.2 Leukaemia cell derived-MVs and EMT 
Another important question that needs to be addressed is why was the 
EMT observed obtained with T cell derived MVs (192). Furthermore, CD8 
positive T cells were found to be capable of inducing tumours with EMT 
characteristics possessed by breast cancer stem cells (193,194). Here in 
the first section of the results chapter I posed the question whether “MVs 
derived from the leukaemia cancer cells are capable of inducing EMT in 
normal prostate epithelial cells’’. 
To determine the effect of leukaemia cell derived-MVs on prostate epithelial 
cells and prospective epithelial to mesenchymal transition change, the EMT 
primarily needs to be defined at the cellular, molecular and genetic le vels. 
EMT is a process in which epithelial cells with apico-basal polarity that are 
attached to the basal membrane differentiate into fibroblast like epithelial 
cells (195). The top-bottom polarity which is the most characteristic 
phenomenon of epithelial cells is disrupted as a result of the disassembly of 
cell-to-cell contacts at adherent junction (E-cadherin) (196).  Furthermore 
the EMT process involves the expression of mesenchymal proteins such as 
Vimentin and fibronectin (197).  
The effects of Jurkat cell-derived MVs on PNT2 cells were examined in the 
context of firstly, the top-bottom polarity and secondly, on the expression of 
the epithelial marker (E-cadherin) and mesenchymal marker (Vimentin). 
Fig.3.3 in the result section presented the effects of Jurkat cell derived-MVs 
on the EMT process in PNT2 cells. This result obtained from the flow 
cytometric analysis shows the molecular changes that take place after 
PNT2 cells were treated with MVs. Comparing control untreated groups 
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with experimental panels clearly demonstrates the down regulation of the 
E-cadherin protein, the hallmark of epithelial cell lines, in the MV treated 
cells. This junctional protein consists of an extracellular domain which is in 
close contact with neighbouring epithelial cells that form the epithelial sheet 
and a single pass trans-membrane domain. The intracellular domain of E-
cadherin consists of two well conserved catenin binding sites (198). The 
cytoplasmic tails of E-cadherin are bound to the actin cytoskeleton protein 
of epithelial cells through the α and β catenin (199). Therefore, alteration in 
the expression of this glycoprotein can disturb the morphology of epithelial 
cells and probably affects intracellular signalling events leading to gene 
expression. Fig.3.4 illustrates the microscopic analysis of epithelial cells 
treated with Jurkat cell-derived MVs. According to this result, (Fig.3.4 D) 
leukaemia cell derived-MVs down regulate the expression of E-cadherin on 
the epithelial cellular junction. This molecular alteration is accompanied by 
cytoskeleton rearrangement of epithelial cells that eventually leads to the 
mesenchymal phenotype. Comparing the treated cells with control 
untreated cells at the morphological level, cells in the experimental group 
lose their top-bottom polarity and acquire front–back polarity. The treated 
group looks stretched out and motile compared with control (Fig.3.4 C) 
exhibiting more classical round shapes with apico-basal polarity.   
According to the results obtained from flow cytometry and fluorescent 
microscopy, PNT2 cells that are cultured with leukaemia cell derived-MVs 
alter their expression of E-cadherin molecules significantly. It is already well 
known that E-cadherin participates in  intracellular signalling events (200). 
One of the signalling pathways partially regulated by this cadherin molecule 
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is the Wnt signalling pathway.  The cytoplasmic domain of E-cadherin is 
bound to the actin cytoskeleton protein through the α and β-catenin (201) 
and the Wnt signalling pathway is regulated by multiple interacting 
signalling proteins. In the absence of Wnt, β-catenin is phosphorylated by 
glycogen synthase kinase in a complex composed of Axin protein and 
adenomatous polyposis coli  protein that causes proteasomal degradation of 
β-catenin (202). In the present of Wnt, the complex of Axin protein, 
adinomatous polyposis coli protein and glycogen synthase kinaseis not 
formed as glycogen synthase kinase is displaced from this complex. This 
displacement in turn causes reduction in the phosphorylation of β-catenin 
and stabilisation of β-catenin (203).  The data presented in this thesis 
suggests for the first time that one of the mechanisms leukaemia cell 
derived-MVs may modulate the Wnt signalling pathway is through the 
cleavage of E-cadherin that occurs in the presence of proteases delivered 
by MVs.  
EMT is defined as a reduction of epithelial marker and increase of 
mesenchymal markers. Therefore, PNT2 cells co-cultured with Jurkat MVs 
were examined in the context of the mesenchymal marker (Vimentin). 
Fig.3.5 B is the result from a FACS analysis which shows a significant 
increase in the expression of Vimentin comparing to control group (Fig.3.5 
A). These results were confirmed by fluorescence microscopic analysis. 
Fig.3.6 shows the expression level of Vimentin in PNT2 cells treated with 
leukaemia cell derived-MVs. Vimentin expression increased to a significant 
level (Fig.3.6 D) compared with control untreated PNT2 cells (Fig.3.6. A). 
Vimentin is type three intermediate fi laments that help to provide cellular 
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structure and movement to mesenchymal cells. This protein is often found 
in mesenchymal cells and has gained much importance as a canonical 
marker of EMT (204). EMT is in fact characterized by the expression of 
Vimentin filaments in epithelial cells which is normally express only keratin 
filaments (205). This protein is encoded by a single gene that is located on 
chromosome 10p. The expression of Vimentin is believed to be regulated 
by three different promoter elements. Association of Vimentin promoter with 
these elements suggests that the Vimentin gene is subjected to a complex 
control (206). As a cytoskeleton structural protein, Vimentin is believed to 
be restricted into the cytoplasm of mesenchymal cells, however, this protein 
can be partially found in the nucleus and cytoplasmic membrane. Therefore, 
this intermediate filament may participates in certain DNA and RNA 
mediated events (207). 
The expression patterns of Vimentin in normal cells and cancerous tissues 
are evaluated as a factor for diagnosis and prognosis (208). In prostate 
cancer, Vimentin expression is highly detectable in metastatic form and 
almost undetectable in benign tumour (209). Vimentin expression is also 
associated with prostate cancer cell motility. Knocking down the expression 
of this filament significantly decreases cells’ motility and invasiveness in 
highly aggressive prostate cancer cell lines (210). 
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6.3 Causes and consequences of EMT 
One the most fundamental questions yet be answered is the nature of the 
elements in Jurkat cell MVs responsible for this phenotypic change in 
epithelial cell lines? I tried to answer this question by examining the role of 
TGF-β signalling pathway on the EMT process as induced by Jurkat MVs. 
Fig.3.7 D presents the epithelial cellular morphology and the E-cadherin 
expression in the MV-treated PNT2 cells, comparing them with control 
untreated PNT2 cells (Fig.3.7A). The experimental panel shows a 
significant reduction in E-cadherin protein and in the context of 
morphological changes the test group no longer grew as an epithelial sheet.  
Fig.3.8 again confirmed the morphological changes of epithelial cells into 
mesenchymal-like cells and expression of Vimentin fi lament. According to 
this result the expression of Vimentin protein decreased after the blocking 
the TGF-β signalling pathway but it was still detectable in the cytosol of 
PNT2 cells which were treated with leukaemia cell derived-MVs. 
 
6.3.1 Leukaemia cell derived-MVs cause endocytosis of E-cadherin in 
target PNT2 cells 
In the second attempt after I found that PNT2 cells exposed to Jurkat cells 
MV causes increases of the cytosolic concentration of Ca2+ at a highly 
significant level, as well as of magnesium, potassium and sodium on the 
target cells (Fig.4.2). I determined the effect of cytosolic Ca2+ concentration 
on the EMT process when PNT2 cells were treated with leukaemia cell 
derived-MVs pre-treated with the calcium chelator, BAPTA-AM. Prior to 
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treatment with leukaemia cell derived-MVs, which causes EMT, PNT2 cells 
treated with calcium chelator (Fig.4.3 C), instead resulted in the 
degradation of E-cadherin as this molecule was endocytosed into the 
cytoplasm of target cells. According to this finding, increasing cytosolic Ca2+ 
concentration by Jurkat MVs might be one of the elements that participate 
in cytosolic E-cadherin degradation on transformed PNT2 cells. Calcium 
plays an important factor in a variety of physiological roles such as 
neurotransmission and cardiac and pathological contractility and also in 
pathological conditions such as cancer invasion and metastasis (211). This 
study described for the first time a mechanism whereby induction of EMT in 
normal prostate epithelial cells was linked with increased intracellular 
concentrations of Ca2+ after treatment with leukaemia cell derived-MVs. 
However, further work is required to answer the question of how leukaemia 
cell derived-MVs cause increased intracellular Ca2+ concentrations in the 
target PNT2 cells, for example, in other words whether these vesicles are 
carrying Ca2+ ions or carrying some Ca2+ mobilizing agent which causes 
activation of Ca2+ channels from the cytoplasmic membrane or from ER of 
the target PNT2 cells. The Ca2+-permeable ion channel TRPM7 is believed 
to be one of the EMT regulators and is also involved in cell migration (212). 
However, there is evidence in the literature suggesting that, silencing the 
TRPM7 did not change the expression of Vimentin in response to  cytosolic 
calcium concentration in breast cancer cells and neither of EMT induction 
and cell migration; the role of Ca2+ signalling is critically important in 
apoptotic resistance (213). Therefore, blocking the interaction of cancer cell 
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derived-MVs with the target cells could offer a new therapeutic approach for 
combating phenotypic changes in normal prostate epithelial cell line. 
6.3.2 PNT2 cells acquire EMT at the expense of their proliferation 
Comparing cell proliferation between PNT2 and tPNT2 (so-called Jurkat MV 
treated PNT2 cells), I found that PNT2 cells treated with 30 µg/ml of Jurkat 
derived-MVs (Fig.4.4.D,E and F) growth was significantly less than control 
PNT2 cells (Fig.4.4. A, B and C). Reduction in PNT2 cell proliferation was 
clearly noticed after 72hrs incubation periods and interestingly this was 
accompanied with PNT2 cell differentiation. There is evidence suggesting 
that E-caderin-mediated cell-cell adhesion generates a cell survival signal, 
the loss of E-caherin and cell-cell contact by the EMT induction likely 
reducing the anchorage independent growth ability of cells. Furthermore, it 
is logical to consider that invading cancer cells transiently lose their cell 
proliferation activity. This study suggests that mesenchymal-epithelial 
transition (MET) under different microenvironment is required for the cancer 
cells to grow again (214). Some researchers blamed histone deacetylases 
(HDACs)-mediated epigenetic mechanisms as having a central role in 
controlling cell proliferation and differentiation in a variety of cells and 
pathogenesis of various diseases (215). Multiple studies propose that 
HDACs are the vital target in a variety of diseases including inflammatory 
conditions, metabolic diseases and malignancy (216). PI3K/AKt and MAPK 
signalling pathways are another important signal transducers for cell 
proliferation and differentiation and also play a key role in the regulation of 
cancer invasion and metastasis (217). Jurkat-MVs induce EMT in normal 
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prostate epithelial cell lines and halt their proliferation activity through the 
HDACs, PI3K/AKt or MAPK signalling pathways.  
 
6.3.3 TPNT2 cells resist programmed cell death induced by serum 
starvation and chemotherapeutic agents 
Serum starvation and docetaxel-induced apoptosis in normal prostate 
epithelial cell lines (Fig.4.4 A) and tPNT2 cells produce considerably high 
levels of resistance against apoptotic signalling which was activated in 
response to serum starvation (Fig.4.4 B). EMT is well documented to be 
associated with death resistance and this phenotypic change could 
potentially play as a pathway to escape programmed cell death under 
physiological and pathological conditions (218). Snail functions as a 
transcription factor to down regulate the expression of pro-apoptotic genes 
such as Bax, Bid, Pten and Puma which can take place in epithelial cells 
that acquire mesenchymal phenotypes (219). Another group found that 
TGF-β induced EMT with the acquisition of apoptotic resistance in 
cholangiocytes (220). TGF-β1 signalling is believed to up-regulate survivin 
to inhibit apoptosis during EMT. Survivin is a member of the Inhibitor of 
Apoptosis Protein (IAP) family and is a key regulator of mitosis and 
programmed cell death and it also regulates the G2/M phase of the cell 
cycle by associating with mitotic spindle microtubules and by direct 
inhibition of caspase-3 and 7 (221). Depletion of survivin using siRNA 
significantly enhanced TGF-β1 induced apoptosis. However, I used 
leukaemia cell derived-MV as a stimulus to induce multiple distinct cellular 
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responses such as induction of apoptosis, cell proliferation, differentiation, 
MMP-9 expression and cell cycle analysis in the PNT2 cells which has not 
hitherto been studied in great detail yet. 
 
6.3.4 MMP-9 expression in TPNT2 cells 
TPNT cells expressed high levels of MMP-9 (Fig.4.8 B and E).  MMPs 
degrade the ECM, cell-ECM and cell-cell structures, thereby causing 
detachment of epithelial cells from surrounding tissues (222). These 
enzymes serve a path-clearing role in facilitating the movement of cells or 
groups of cells through the ECM (223). This also results in cleavage of 
adhesion proteins such as E-cadherin which leads to the release of 
individual epithelial cells from the epithelial sheets and initiates outside-in 
signalling pathways that cause changes in gene transcription patterns. 
MMP-9 is believed to dock to the hyaluronan receptor CD44, mediating  
proteolytic activation of TGF-β and promotion of tumour invasion and 
metastasis and angiogenesis in carcinoma models.  MMPs are linked with 
EMT in cancer progression through three distinct mechanisms, (A), 
elevated levels of MMPs can directly causes EMT i n the tumour 
microenvironment, (B), Cancer cells undergoing EMT produce high levels 
of MMPs which facilitates cell invasion and metastasis, and (C), EMT can 
generate activated stromal cells that drive cancer progression by MMP 
production (224). Within this contest, TPNT2 cells expressing high levels of 
MMP-9 after EMT induction, using leukaemia cell derived-MV as a stimulus, 
may transform into cancer cells. Statements A and C which quoted that 
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‘high level MMPs induce EMT and EMT activates stromal cell’ could not be 
true, because, in both conditions I have PNT2 controls and as for statement 
C, there no stromal cells to get activated and yet MMP-9 is produced by 
TPNT2 cells. 
 
6.3.5 TPNT2 and cell cycle regulation 
Figs. 4.9 C  and D show misregulation of the cell cycle in tPNT2 cells and 
this was obviously clear on comparison with normal prostate epithelial cells. 
The significant change was the high percentage (69%) of TPNT cells 
arrested in the G2/M phases of the cell cycle. Cell cycle phase is believed 
to be a key event in the determination of EMT and apoptotic pathways 
(225). Treatment of epithelial cells with TGF-β induced apoptosis of the 
target epithelial cells in the G2/M phase of the cell cycle  and if these cell 
are in the G1/S phase of the cell cycle they transfer to EMT (226). In my 
study however, there is a very small population (11%) of TPNT2 cells 
present in G1/S and 69% of TPNT cells were arrested in G2/M phase of the 
cell cycle. Most interestingly, these cells produced significantly high levels 
of resistance against apoptotic signals. This study could suggest a rethink 
about the role of TGF-β present on leukaemia cell derive-MVs causing EMT 
on PNT2 cells. G2/M phase of the cell cycle serves as a checkpoint for cells 
with DNA damage to prevent them from entering mitosis with genomic DNA 
damage. The activity of CDK1 complex is crucial in regulating the G2-phase 
of transition. Almost all researchers agree that these cells with DNA 
damage are arrested in the G2/ phases of the cell cycle, so that treatment 
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of PNT2 cells with Jurkat MVs causes 69% arrest in the G2/M phase of the 
cell cycle meaning that treatment of these cells with leukaemia cell derived-
MVs causes DNA damage to the target TPNT2 cells. 
 
6.4 Carcinoma cell derived-MVs and the tumour microenvironment 
6.4.1 A549 cell derived-MVs transform fibroblasts to myofibroblasts 
Treatment of Non-Small lung cancer cells derived-MVs caused 
transformation of primary lung fibroblasts into myofibroblasts (Figs.6.2 and 
6.3). Transformation of primary fibroblasts was confirmed by the expression 
of α-SMA cytoskeleton protein. Αlpha-SMA protein is the central feature of 
activated fibroblasts which is the central mechanism of the tissue repair 
process and also it is a response from the microenvironment to the 
epithelial tumour (159,227). Using α-SMA expression as a marker I found 
there to be a sub-population of cancer-associated fibroblasts in the tumour 
stroma. However, in the complex microenvironment of wound healing and 
tumour it cannot be used because smooth muscle cells, which are 
abundant in wound healing and tumour stroma, also express α-SMA protein 
(160).  The consequences of this phenotypic change in tumour stroma lead 
to tumour development and cancer metastasis. Myofibroblasts are reported 
to produce significantly high levels of a variety of growth factors such as  
HGF, EGF, VEGF, FGF and cytokines such TGF-β1 and pro-inflammatory 
cytokines including CXCL 14, IL-1, IL-6 and IL-8 which promote tumour 
progression and metastasis (228,229). Furthermore, myofibroblastsare 
involved in the remodelling of the ECM and foster cancer invasion by 
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producing high levels of MMPs such as MMP-1, MMP-2, MMP-3, MMP-9, 
MMP-13, and MMP-14 (230). In addition to changing the chemical 
composition of stroma, the stiffening action as a result of stress fibre 
production has an important role for tumour production (231). 
 
6.4.2 Myofibroblasts and Fibroblast Growth Factor expression 
One of the consequences of myofibroblast activation is the excessive 
production of fibroblast growth factor (FGF) which cooperates with other 
GFs, cytokines and pro-inflammatory cytokines which collectively facilitate 
tumour invasion and metastasis (228). Treatment of MRC5 cells with lung 
carcinoma cell derived-MVs in Fig.5.5 demonstrated that myofibroblasts 
expressed high levels of FGF compared to primary fibroblasts. FGF 
signalling is involved in many physiological developmental processes 
including morphogenesis in organs such as kidneys, lung, and mammary 
glands (232). Amplification of FGF ligands and receptors is observed in 
human breast and lung cancer samples, the FGF ligands being located on 
chromosome 11q13 which are amplified in 15% of human breast cancers 
and FGFR genes which are located on chromosome 8p12, amplified in 10% 
of human breast cancers (233). Recent studies suggest that ectopic 
expression of FGFR1 correlates with increased protein expression and that 
blocking FGFR activity in breast cancer leads to decreased growth and 
survival of target cells (233). Immunohistochemical analysis in human 
breast cancer demonstrated increased expression of FGF in 62% of basal 
like breast cancer tissue (234). Within this context, treatment of primary 
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lung fibroblasts with 50 µg/ml Non-small lung cancer cells derived-MVs for 
7 days significantly increased the expression of FGF on target MRC5 cells.  
However, further work is needed to be done to understand the mechanism 
of increased expression of FGF in myofibroblasts, whether it is due to the 
FGF receptor transfer or FGF ligand transfer from A549 cancer cells 
through A549 cell derived-MVs to primary lung fibroblasts.  
 
6.4.3 Lung cancer cells remodelling the ECM through their MV release 
Stroma surrounding the solid tumour represents an active element in the 
process of tumour development (235,236). Myofibroblasts are the main cell 
type in the ECM involved in the development of reactive stroma (237). 
Cancer cells have the ability to induce fibroblasts to ac tive phenotype 
myofibroblasts (238). In this study I have shown that MVs derived from 
myofibroblasts can induce normal fibroblasts to change into reactive 
myofibroblasts (Fig.5.6). The current study also examined some elements 
present in the tumour microenvironment such as MVs secreted from 
immune cells that could possibly block the effects of cancer cell derived 
MVs on stromal cells (Fig.5.7).  According to this study, the effects of 
myofibroblast MVs on primary lung fibroblasts were positively correlated 
with the presence of α-SMA myfibroblast MVs (Fig.5.8). It may also be that 
ECM mediated cell-cell communication between tissues from the same or 
different organs could deliver bioactive molecules (239). However, the 
mechanism for this interaction has not yet been explained in much detail. I 
tried to observe the interaction of MVs and target cells for 7 consecutive 
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days and found that the delivering of bioactive molecules most likely takes 
place by the fusion of MVs with target cells (Fig.5.8F). The most important 
question yet to be answered is whether these MVs are used by cells as a 
source of lipid bilayer to renew their membrane, or MVs as biologically 
active molecules establish a ligand-receptor partnership and cause these 
changes. An intensive research at cellular and molecular level needs to be 
carried out to answer this question.   
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